0000898770-12-000004.txt : 20120201 0000898770-12-000004.hdr.sgml : 20120201 20120201124539 ACCESSION NUMBER: 0000898770-12-000004 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20111231 FILED AS OF DATE: 20120201 DATE AS OF CHANGE: 20120201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHARPS COMPLIANCE CORP CENTRAL INDEX KEY: 0000898770 STANDARD INDUSTRIAL CLASSIFICATION: HAZARDOUS WASTE MANAGEMENT [4955] IRS NUMBER: 742657168 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34269 FILM NUMBER: 12561733 BUSINESS ADDRESS: STREET 1: 9220 KIRBY DRIVE STREET 2: STE 500 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 713-432-0300 MAIL ADDRESS: STREET 1: 9220 KIRBY DRIVE STREET 2: STE 500 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: US MEDICAL SYSTEMS INC DATE OF NAME CHANGE: 19970128 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL POLYMERS TECHNOLOGIES INC DATE OF NAME CHANGE: 19930916 10-Q 1 form10qdec2011.htm SHARPS COMPLIANCE FORM 10-Q 12 31 2011 form10qdec2011.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________________

FORM 10-Q

 
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended December 31, 2011
 
OR

 
    TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from   to  .

Commission File Number:  001-34269
_______________________

SHARPS COMPLIANCE CORP.
(Exact name of registrant as specified in its charter)


Delaware
74-2657168
(State or other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)
 



9220 Kirby Drive, Suite 500, Houston, Texas
77054
(Address of principal executive offices)
(Zip Code)
 
(713) 432-0300
(Registrant’s telephone number, including area code)

Indicate by check mark if the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  ý  No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ý No 

Indicate by check mark whether the registrant is a large accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Securities Exchange Act of 1934.
             
Large Accelerated Filer o
 
Accelerated Filer ý
 
Non-accelerated Filer o
 (Do not check if a smaller reporting company)
 
Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes o No ý

As of January 30, 2012, there were 15,096,291 outstanding shares of the Registrant's common stock, par value $0.01 per share.

 
 

 




 
     
PAGE
     
 
     
 
3
     
 
4
     
 
5
     
 
6
     
 
7
     
 
8
     
12
 
 
 
 
21
     
21
     
 
     
21
     
21
     
21
     
22
     
 
23
     
     




SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
(In thousands, except par value)


             
   
December 31,
   
June 30,
 
   
2011
   
2011
 
   
(Unaudited)
       
ASSETS
           
CURRENT ASSETS
           
  Cash and cash equivalents
  $ 18,343     $ 18,280  
  Accounts receivable, net of allowance for doubtful accounts of $24 and
               
       $26, respectively
    2,600       3,065  
  Inventory
    2,483       1,770  
  Prepaid and other current assets
    917       857  
  Deferred income taxes
    233       203  
    TOTAL CURRENT ASSETS
    24,576       24,175  
                 
PROPERTY, PLANT AND EQUIPMENT, net
    4,993       5,350  
                 
DEFERRED INCOME TAXES, non-current
    890       748  
                 
INTANGIBLE ASSETS, net of accumulated amortization of $242 and
               
      $227, respectively
    376       325  
                 
TOTAL ASSETS
  $ 30,835     $ 30,598  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
CURRENT LIABILITIES
               
  Accounts payable
  $ 1,193     $ 965  
  Accrued liabilities
    1,331       1,260  
  Deferred revenue
    1,773       1,724  
    TOTAL CURRENT LIABILITIES
    4,297       3,949  
                 
LONG-TERM DEFERRED REVENUE
    329       401  
                 
OTHER LONG TERM LIABILITIES
    240       383  
                 
    TOTAL LIABILITIES
    4,866       4,733  
                 
COMMITMENTS AND CONTINGENCIES
               
                 
STOCKHOLDERS' EQUITY
               
  Common stock, $0.01 par value per share; 20,000 shares authorized;
               
      15,096 and 15,053 shares issued and outstanding, respectively
    151       151  
  Additional paid-in capital
    22,003       21,602  
  Retained earnings
    3,815       4,112  
    TOTAL STOCKHOLDERS' EQUITY
    25,969       25,865  
                 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
  $ 30,835     $ 30,598  



The accompanying notes are an integral part of these condensed consolidated financial statements.



SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
(In thousands, except per-share data)


   
Three-Months
 
   
Ended December 31,
 
   
2011
   
2010
 
   
(Unaudited)
 
             
REVENUES
  $ 6,212     $ 4,611  
                 
COSTS AND EXPENSES
               
  Cost of revenues
    4,065       3,385  
  Selling, general and administrative
    1,997       2,339  
  Depreciation and amortization
    116       87  
    TOTAL COSTS AND EXPENSES
    6,178       5,811  
                 
OPERATING INCOME (LOSS)
    34       (1,200 )
                 
OTHER INCOME
               
  Other income
    9       15  
    TOTAL OTHER INCOME
    9       15  
                 
INCOME (LOSS) BEFORE INCOME TAXES
    43       (1,185 )
                 
INCOME TAX EXPENSE (BENEFIT)
               
  Current
    2       (981 )
  Deferred
    13       603  
    TOTAL INCOME TAX EXPENSE (BENEFIT)
    15       (378 )
                 
                 
NET INCOME (LOSS)
  $ 28     $ (807 )
                 
NET INCOME (LOSS) PER COMMON SHARE
               
    Basic
  $ 0.00     $ (0.05 )
                 
    Diluted
  $ 0.00     $ (0.05 )
                 
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET
               
    INCOME (LOSS) PER COMMON SHARE:
               
                 
    Basic
    15,077       14,920  
    Diluted
    15,404       14,920  




The accompanying notes are an integral part of these condensed consolidated financial statements.



SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
(In thousands, except per-share data)


   
Six-Months
 
   
Ended December 31,
 
   
2011
   
2010
 
   
(Unaudited)
 
             
REVENUES
  $ 11,955     $ 9,844  
                 
COSTS AND EXPENSES
               
  Cost of revenues
    7,989       6,806  
  Selling, general and administrative
    4,207       4,714  
  Special charge
    -       570  
  Depreciation and amortization
    223       176  
    TOTAL COSTS AND EXPENSES
    12,419       12,266  
                 
OPERATING LOSS
    (464 )     (2,422 )
                 
OTHER INCOME
               
  Other income
    6       28  
    TOTAL OTHER INCOME
    6       28  
                 
LOSS BEFORE INCOME TAXES
    (458 )     (2,394 )
                 
INCOME TAX EXPENSE (BENEFIT)
               
  Current
    -       (1,342 )
  Deferred
    (161 )     552  
    TOTAL INCOME TAX BENEFIT
    (161 )     (790 )
                 
                 
NET LOSS
  $ (297 )   $ (1,604 )
                 
NET LOSS PER COMMON SHARE
               
    Basic
  $ (0.02 )   $ (0.11 )
                 
    Diluted
  $ (0.02 )   $ (0.11 )
                 
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET
               
    LOSS PER COMMON SHARE:
               
                 
    Basic
    15,071       14,914  
    Diluted
    15,071       14,914  


SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
(In thousands, except share data)



 
 
                               
               
Additional
         
Total
 
   
Common Stock
   
Paid-in
   
Retained
   
Stockholders'
 
   
Shares
   
Amount
   
Capital
   
Earnings
   
Equity
 
                               
Balances, June 30, 2010
    14,891,754     $ 149     $ 19,705     $ 7,087     $ 26,941  
                                         
Exercise of stock options
    62,500       1       48       -       49  
                                         
Stock-based
                                       
  compensation
    -       -       871       -       871  
                                         
Issuance of restricted stock
    99,062       1       (1 )     -       -  
                                         
Excess tax benefit from
                                       
  stock-based award activity
    -       -       979       -       979  
                                         
Net Loss
    -       -       -       (2,975 )     (2,975 )
                                         
Balances, June 30, 2011
    15,053,316       151       21,602       4,112       25,865  
                                         
Exercise of stock options*
    14,103       -       13       -       13  
                                         
Stock-based
                                       
  compensation*
    -       -       376       -       376  
                                         
Issuance of restricted stock*
    28,872       -       -       -       -  
                                         
Excess tax benefit from
                                       
  stock-based award activity*
    -       -       12       -       12  
                                         
Net Loss*
    -       -       -       (297 )     (297 )
                                         
Balances, December 31, 2011*
    15,096,291     $ 151     $ 22,003     $ 3,815     $ 25,969  
                                         
* unaudited
                                       





The accompanying notes are an integral part of these condensed consolidated financial statements.



SHARPS COMPLIANCE CORP. AND SUBSIDIARIES
(In thousands)


   
Six-Months Ended
 
   
December 31,
 
   
2011
   
2010
 
   
(Unaudited)
 
CASH FLOWS FROM OPERATING ACTIVITIES
           
  Net loss
  $ (297 )   $ (1,604 )
  Adjustments to reconcile net loss to net cash provided by (used in)
               
  operating activities:
               
    Depreciation and amortization
    548       499  
    Loss on disposal of property, plant and equipment
    13       -  
    Stock-based compensation expense
    376       507  
    Excess tax benefits from stock-based award activity
    (12 )     (964 )
    Deferred tax (benefit) expense
    (161 )     552  
  Changes in operating assets and liabilities:
               
    Decrease in accounts receivable
    465       19  
    Increase in inventory
    (713 )     (383 )
    Increase in prepaid and other current assets
    (60 )     (441 )
    Increase in accounts payable and accrued liabilities
    156       861  
    (Decrease) increase in deferred revenue
    (23 )     99  
    NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
    292       (855 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES
               
    Purchase of property, plant and equipment
    (189 )     (248 )
    Additions to intangible assets
    (65 )     (84 )
    NET CASH USED IN INVESTING ACTIVITIES
    (254 )     (332 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES
               
    Excess tax benefits from stock-based award activity
    12       964  
    Proceeds from exercise of stock options
    13       2  
    NET CASH PROVIDED BY FINANCING ACTIVITIES
    25       966  
                 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
    63       (221 )
                 
CASH AND CASH EQUIVALENTS, beginning of period
    18,280       18,068  
                 
CASH AND CASH EQUIVALENTS, end of period
  $ 18,343     $ 17,847  




The accompanying notes are an integral part of these condensed consolidated financial statements.


SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTE 1 - ORGANIZATION AND BACKGROUND

The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com, Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.) and Sharps Safety, Inc. (collectively, “Sharps”, “We” or the  “Company”).  All significant intercompany accounts and transactions have been eliminated upon consolidation.

NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under accounting principles generally accepted in the United States of America for complete financial statements.  In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of December 31, 2011, the results of its operations and cash flows for the three and six months ended December 31, 2011 and 2010 and stockholders’ equity for the year ended June 30, 2011 and six months ended December 31, 2011. The results of operations for the three and six months ended December 31, 2011 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2012.  These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended June 30, 2011.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

REVENUE RECOGNITION

The Company recognizes revenue from product sales when goods are shipped or delivered, and title and risk of loss pass to the customer except for those sales via multiple-deliverable arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.

Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served.

The Company recognizes revenue in accordance with guidance on revenue recognition of multiple-deliverable revenue arrangements. On July 1, 2010, the Company adopted ASU No. 2009-13 which further clarified guidance on revenue recognition for multiple-deliverable revenue arrangements, changing the way the Company allocates arrangement consideration to the separate units of accounting.  Under this guidance, certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ (formerly the Sharps Disposal by Mail Systems®) and various TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation  and (3) treatment service.

Prior to July 1, 2010, the individual fair value of the transportation and treatment services were determined by the sales price of the service offered by third parties, with the fair value of the compliance and container being the residual value.  Beginning July 1, 2010, under the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting.  The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price.  Because an estimated selling price must be set for each unit, the residual method used previously by the Company to allocate consideration to the compliance and container system is no longer allowed.  The selling price for the transportation revenue and the treatment revenue, which utilizes third party evidence, did not change from the prior method.  The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities.

Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership.  Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s facility. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s facility. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container.  Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed.  The current and long-term portions of deferred revenues are determined through regression analysis and historical trends.  Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned.  Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.
 
 
ACCOUNTS RECEIVABLE

Accounts receivable consist primarily of amounts due to us from our normal business activities.  Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer.  The Company maintains an allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past collection history and specific risks identified among uncollected accounts.  Accounts receivable are charged to the allowance for doubtful accounts when the Company has determined that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.
 
NOTE 4 – RECENTLY ISSUED ACCOUNTING STANDARDS

There are no recently issued accounting pronouncements that impact the Company’s condensed consolidated financial statements as of December 31, 2011.

NOTE 5 - INCOME TAXES

The Company’s effective tax rate for the six months ended December 31, 2011 was 35.2% compared to 33.0% for the six months ended December 31, 2010 and 33.8% for the fiscal year ended June 30, 2011.  The effective tax rate for the six months ended December 31, 2011 is higher due the expected impact of state income taxes as a result of forecasted fiscal year 2012 income.

NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT

The Company’s Credit Agreement with Wells Fargo Bank, National Association provides for a two-year, $5.0 million line of credit facility, the proceeds of which may be utilized for: (i) working capital, (ii) capital expenditures, (iii) letters of credit (up to $500,000), (iv) acquisitions (up to $1,000,000) and (v) general corporate purposes. As of December 31, 2011, the Company had no outstanding borrowings, $106 thousand in letters of credit outstanding, and $4.9 million of credit available.

Indebtedness under the Credit Agreement is secured by substantially all of the Company’s assets. Borrowings bear interest at either (i) a fluctuating rate per annum equal to LIBOR plus a margin of 250 basis points or (ii) at the Company’s option, a fixed rate for a 30, 60, or 90 day period set at the option date’s LIBOR plus a margin of 250 basis points. Any outstanding revolving loans, and accrued and unpaid interest, will be due and payable on July 15, 2012, the maturity date of the Credit Agreement. The Company pays a fee of 0.2% per annum on the unused amount of the line of credit. The Company estimates that the interest rate applicable to the borrowings under the Credit Agreement would be approximately 3.1% as of December 31, 2011.

The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a minimum level of tangible net worth of $21 million and not exceed a ratio of liabilities to tangible net worth of 1.0 to 1.0. As of December 31, 2011, the Company is in compliance with all financial covenants. The Credit Agreement also contains customary events of default. Upon the occurrence of an event of default that remains uncured after any applicable cure period, the lenders’ commitment to make further loans may terminate and the Company may be required to make immediate repayment of all indebtedness to the lenders. The Credit Agreement expires on July 15, 2012.

NOTE 7 – STOCK-BASED COMPENSATION

Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant).  Total stock-based compensation for the three months ended December 31, 2011 and 2010 was $257 thousand ($18 thousand included in cost of revenues and $239 thousand included in general and administrative expense in the Company’s condensed consolidated statement of operations) and $292 thousand ($25 thousand included in cost of revenues and $267 thousand included in general and administrative expense in the Company’s condensed consolidated statement of operations), respectively. Total stock-based compensation for the six months ended December 31, 2011 and 2010 was $376 thousand ($38 thousand included in cost of revenues and $338 thousand included in general and administrative expense in the Company’s condensed consolidated statement of operations) and $507 thousand ($45 thousand included in cost of revenues and $462 thousand included in general and administrative expense in the Company’s condensed consolidated statement of operations), respectively.

Reductions in taxes payable resulting from tax deductions that exceed the recognized tax benefit associated with compensation expense (excess tax benefits) are classified as financing cash flows and as an increase to additional paid in capital. The Company’s excess tax benefits included in its cash flows from financing activities for the six months ended December 31, 2011 and 2010 was $12 thousand and $964 thousand, respectively.

In conjunction with the retirement and separation agreement of Dr. Burton Kunik, effective September 30, 2010, the Company recognized an additional $73 thousand in stock-based compensation expense which is included in the Special Charge on the accompanying statement of operations for the six months ended December 31, 2010.

 
NOTE 8 - EARNINGS PER SHARE
 
Earnings per share are measured at two levels: basic per share and diluted per share. Basic per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted per share is computed by dividing net income by the weighted average number of common shares after considering the additional dilution related to common stock options and restricted stock. In computing diluted earnings per share, the outstanding common stock options are considered dilutive using the treasury stock method. Vested restricted shares are included in basic common shares outstanding, and unvested restricted shares are included in the diluted common shares outstanding, if the effect is dilutive.
 
The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):


   
Three-Months Ended
   
Six-Months Ended
 
   
December 31,
   
December 31,
 
   
2011
   
2010
   
2011
   
2010
 
   
(Unaudited)
   
(Unaudited)
 
                         
Net income (loss), as reported
  $ 28     $ (807 )   $ (297 )   $ (1,604 )
                                 
Weighted average common shares outstanding
    15,077       14,920       15,071       14,914  
Effect of dilutive stock options
    327       -       -       -  
Weighted average diluted common shares outstanding
    15,404       14,920       15,071       14,914  
                                 
Net income (loss) per common share
                               
    Basic
  $ 0.00     $ (0.05 )   $ (0.02 )   $ (0.11 )
    Diluted
  $ 0.00     $ (0.05 )   $ (0.02 )   $ (0.11 )
                                 
Employee stock options excluded from computation
                               
 of dilutive income per share amounts because their
                               
   effect would be anti-dilutive
    513       412       538       412  

 
 
NOTE 9 - EQUITY TRANSACTIONS

During the three and six months ended December 31, 2011 and 2010, stock options to purchase shares of the Company’s common stock were exercised as follows:


                         
   
Three-Months Ended
   
Six-Months Ended
 
   
December 31,
   
December 31,
 
   
2011
   
2010
   
2011
   
2010
 
   
(Unaudited)
   
(Unaudited)
 
                         
Options exercised
    -       -       14,103       2,000  
Proceeds (in thousands)
  $ -     $ -     $ 13     $ 2  
Average exercise price per share
  $ -     $ -     $ 0.95     $ 0.84  


As of December 31, 2011, there was $991 thousand of stock option and restricted stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 2.4 years.

NOTE 10 – INVENTORY

The components of inventory are as follows (in thousands):

 
   
December 31,
   
June 30,
 
   
2011
   
2011
 
   
(Unaudited)
       
Raw materials
  $ 1,271     $ 790  
Finished goods
    1,212       980  
Total
  $ 2,483     $ 1,770  
NOTE 11 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, not to be materially different from their carrying values at year-end due to their short-term nature.



ITEM  2.


INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains certain forward-looking statements and information relating to the Company and its subsidiaries that are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. When used in this report, the words “anticipate”, “believe”, “expect”, “estimate”, “project” and “intend” and words or phrases of similar import, as they relate to the Company or its subsidiaries or Company management, are intended to identify forward-looking statements.  Such statements reflect the current risks, uncertainties and assumptions related to certain factors, including without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein.  Based upon changing conditions, should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, expected, estimated or intended.  The Company does not intend to update these forward-looking statements.

GENERAL

Sharps Compliance Corp. is a leading full-service provider of cost-effective solutions designed for the proper management of for medical waste, used healthcare materials and unused dispensed medications. Our solutions facilitate the proper treatment of numerous types of medical waste, used healthcare materials and unused dispensed medications, including hypodermic needles, lancets and other devices or objects used to puncture or lacerate the skin, or sharps, and unused dispensed prescription and over-the-counter drugs and medications.  We serve customers in multiple markets such as home health care, retail clinics and immunizing pharmacies, pharmaceutical manufacturers, professional offices (physicians, dentists and veterinarians), hospitality (including assisted living facilities, hotels, motels and restaurants), government (federal, state and local), consumers, commercial, industrial and agriculture, and distributors to many of the aforementioned markets.  We assist our customers in determining which of our distinct solution offerings best fit their needs for the collection, storage, return transportation and treatment of their or their patients’ medical waste and unused dispensed medications.  Our differentiated approach provides our customers the flexibility to return and ultimately properly treat their or their patients’ medical waste or unused dispensed medications through pre-paid mail services primarily through the United States Postal Service (“USPS”). Furthermore, we provide comprehensive tracking and reporting tools that enable our customers to meet complex medical waste disposal and unused dispensed patient medication compliance requirements.  We believe the fully-integrated nature of our operations is a key factor leading to our success and continued recurring revenue growth. The Company’s primary solutions include Sharps Recovery System™ (formerly Sharps Disposal by Mail System®), TakeAway Recovery System™, Complete Needle™ Collection and Disposal System, TakeAway Environmental Return System™, Rx TakeAway Recovery and Reporting System™, Sharps Recovery System™ Needle Collection and Mailback Disposal, Sharps® MWMS™, Sharps Secure® Needle Collection and Containment System, Pitch-It IV™ Poles, Trip LesSystem®, Sharps® Pump and Asset Return System, IsoWash® Linen Recovery System and Biohazard Spill Clean-Up Kit and Disposal System.



RESULTS OF OPERATIONS

The following analyzes changes in the consolidated operating results and financial condition of the Company during the three and six months ended December 31, 2011 and 2010. The following table sets forth, for the periods indicated, certain items from the Company's Condensed Consolidated Statements of Operations, dollars in thousands and percentages expressed as a percentage of revenue:

   
Three-Months Ended December 31,
   
Six-Months Ended December 31,
 
   
2011
   
%
   
2010
   
%
   
2011
   
%
   
2010
   
%
 
   
(Unaudited)
   
(Unaudited)
 
                                                 
Revenues
  $ 6,212       100.0 %   $ 4,611       100.0 %   $ 11,955       100.0 %   $ 9,844       100.0 %
                                                                 
Cost of revenues
    4,065       65.4 %     3,385       73.4 %     7,989       66.8 %     6,806       69.1 %
Gross profit
    2,147       34.6 %     1,226       26.6 %     3,966       33.2 %     3,038       30.9 %
                                                                 
SG&A expense
    1,997       32.1 %     2,339       50.7 %     4,207       35.2 %     4,714       47.9 %
Special charge
    -       0.0 %     -       0.0 %     -       0.0 %     570       5.8 %
Depreciation and amortization
    116       1.9 %     87       1.9 %     223       1.9 %     176       1.8 %
                                                                 
Operating income (loss)
    34       0.5 %     (1,200 )     (26.0 %)     (464 )     (3.9 %)     (2,422 )     (24.6 %)
                                                                 
Other income
    9       0.1 %     15       0.3 %     6       0.1 %     28       0.3 %
                                                                 
Income (loss) before income taxes
  $ 43       0.7 %   $ (1,185 )     (25.7 %)   $ (458 )     (3.8 %)   $ (2,394 )     (24.3 %)
Income tax expense (benefit)
    15       0.2 %     (378 )     (8.2 %)     (161 )     (1.3 %)     (790 )     (8.0 %)
Net income (loss)
  $ 28       0.5 %   $ (807 )     (17.5 %)   $ (297 )     (2.5 %)   $ (1,604 )     (16.3 %)
                                                                 
Net income (loss) per share
                                                               
     Basic
  $ 0.00             $ (0.05 )           $ (0.02 )           $ (0.11 )        
     Diluted
  $ 0.00             $ (0.05 )           $ (0.02 )           $ (0.11 )        
                                                                 
Weighted Average
Shares Outstanding
                                                               
     Basic
    15,077               14,920               15,071               14,914          
     Diluted
    15,404               14,920               15,071               14,914          


THREE MONTHS ENDED DECEMBER 31, 2011 AS COMPARED TO THREE MONTHS ENDED DECEMBER 31, 2010

Total revenues for the three months ended December 31, 2011 of $6.2 million increased by $1.6 million, or 34.7%, over the total revenues for the three months ended December 31, 2010 of $4.6 million. Billings by market are as follows (in thousands):

   
Three-Months Ended December 31,
 
   
(Unaudited)
 
   
2011
   
2010
   
Variance
 
                   
BILLINGS BY MARKET:
                 
Home Health Care
  $ 1,740     $ 1,642     $ 98  
Retail
    1,303       771       532  
U.S Government Contract
    722       380       342  
Core Government
    90       69       21  
Professional
    720       519       201  
Pharmaceutical
    709       47       662  
Assisted Living / Hospitality
    269       293       (24 )
Other
    434       331       103  
Subtotal
    5,987       4,052       1,935  
GAAP Adjustment *
    225       559       (334 )
Revenue Reported
  $ 6,212     $ 4,611     $ 1,601  


*Represents the net impact of the revenue recognition adjustment required to arrive at reported generally accepted accounting principles (“GAAP”) revenue.  
 
 
 
Customer billings include all invoiced amounts associated with products shipped during the period reported.  GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with products returned for treatment and destruction.  The difference between customer billings and GAAP revenue is reflected in the Company’s balance sheet as deferred revenue.  See Note 3 “Revenue Recognition” in “Notes to Condensed Consolidated Financial Statements”.

This Quarterly Report on Form 10-Q contains certain financial information not derived in accordance with GAAP, including customer billings information.  The Company believes this information is useful to investors and other interested parties as customer billings represents all invoiced amounts associated with products shipped during the period reported. Such information should not be considered as a substitute for any measures derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included above.

The increase in revenues is primarily attributable to increased billings in the Pharmaceutical ($0.7 million), Retail ($0.5 million), U.S. Government contract ($0.3 million), Professional ($0.2 million) and Home Health Care ($0.1 million) markets.  The increase in the Pharmaceutical market billings is due to the timing of customer orders including resupply orders for existing patient support programs and the launch during the quarter of one of three new patient support programs announced in August and October 2011. The programs include the direct fulfillment of the Sharps Recovery System® to the pharmaceutical manufacturers’ program participants which provides the proper containment, return and treatment of the needles or injection devices utilized in therapy. The increase in the Retail market is primarily due to higher sales to pharmacies in support of the 2011 flu shot season. The percentage of flu shots and other injections administered in the retail pharmacy setting continues to grow as retailers are moving aggressively to provide more health care services to their customers. Further contributing to the increase in retail billings for the quarter over prior year is a shift in ordering patterns by retail pharmacies toward a just-in-time basis as opposed to stocking up on systems as they had previously ordered. U.S. Government contract billings are associated with the Company’s contract with a major U.S. government agency announced in February 2009. The increase in the U.S. Government contract market billings is due to the start of the second option year, which includes a higher payment for increased maintenance service fees than the first option year. The increase in the Professional market was a direct result of the Company’s targeted telemarketing activities, new website and corresponding promotional activities to educate doctors, dentists and veterinarians on the significant cost advantage and the convenience of the Sharps Recovery System™ over the traditional pick-up service. The increase in billings in the Home Health Care market was primarily due to timing of sales to home health care related distributors addressing the growing trend of patient volumes in the home health care industry. Revenue was negatively impacted by an increase in the GAAP adjustment of $0.3 million primarily related to the mix of products sold in the prior year and the impact of deferrals.

Cost of revenues for the three months ended December 31, 2011 of $4.1 million was 65.4% of revenues.  Cost of revenues for the three months ended December 31, 2010 of $3.4 million was 73.4% of revenues.  The higher gross margin for the quarter ended December 31, 2011 of 34.6% (versus 26.6% for the quarter ended December 31, 2010) was due to the leverage inherent in the business due to increased sales volume.

Selling, general and administrative (“SG&A”) expenses for the three months ended December 31, 2011 of $2.0 million, decreased by $0.3 million, from SG&A expenses of $2.3 million for the three months ended December 31, 2010.  The decrease in SG&A is primarily due to (i) decreased professional expenses of $0.2 million (primarily due to regulatory and consulting fees, legal fees, audit and related fees and other sales-related consulting fees) and (ii) lower compensation and benefit expense including payroll tax of $0.1 million (primarily due to timing of employee hires and terminations and stock-based compensation).

The Company generated operating income of $34 thousand for the three months ended December 31, 2011 compared to an operating loss of $1.2 million for the three months ended December 31, 2010.  The operating margin was 0.5% for the three months ended December 31, 2011 compared to (26.0%) for the three months ended December 31, 2010. The improvement in operating income is a result of the higher sales volume as well as strong cost discipline and focused use of resources on targeted markets primarily Retail, Pharmaceutical, Professional and Core Government markets (discussed above).

The Company generated income before tax of $43 thousand for the three months ended December 31, 2011 versus a loss before tax of $1.2 million for the three months ended December 31, 2010. The improvement in income before tax is a result of the increase in operating income (discussed above).

The Company’s effective tax rate for the three months ended December 31, 2011 was 34.9% compared to 31.9% for the three months ended December 31, 2010 and 33.8% for the fiscal year ended June 30, 2011. The effective tax rate for the three months ended December 31, 2011 is higher due to the expected impact of state income taxes as a result of forecasted fiscal year 2012 income.
 
The Company generated net income of $28 thousand for the three months ended December 31, 2011 compared to a net loss of $0.8 million for the three months ended December 31, 2010.  The improvement is a result of improved operating income (discussed above).

The Company reported diluted income per share of $0.00 for the three months ended December 31, 2011 versus diluted loss per share of ($0.05) for the three months ended December 31, 2010.  The improvement in diluted earnings per share is a result of net income in the current quarter (discussed above).



SIX MONTHS ENDED DECEMBER 31, 2011 AS COMPARED TO SIX MONTHS ENDED DECEMBER 31, 2010

Total revenues for the six months ended December 31, 2011 of $12.0 million increased by $2.1 million, or 21.4%, over the total revenues for the six months ended December 31, 2010 of $9.8 million. Billings by market are as follows (in thousands):

 
 


   
Six-Months Ended December 31,
 
   
(Unaudited)
 
   
2011
   
2010
   
Variance
 
                   
BILLINGS BY MARKET:
                 
Home Health Care
  $ 3,507     $ 3,655     $ (148 )
Retail
    3,026       2,663       363  
U.S. Government Contract
    1,444       760       684  
Core Government
    215       289       (74 )
Professional
    1,422       991       431  
Pharmaceutical
    979       177       802  
Assisted Living / Hospitality
    569       573       (4 )
Other
    703       680       23  
Subtotal
    11,865       9,788       2,077  
GAAP Adjustment *
    90       56       34  
Revenue Reported
  $ 11,955     $ 9,844     $ 2,111  

*Represents the net impact of the revenue recognition adjustment required to arrive at reported generally accepted accounting principles (“GAAP”) revenue.  Customer billings include all invoiced amounts associated with products shipped during the period reported.  GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with products returned for treatment and destruction.  The difference between customer billings and GAAP revenue is reflected in the Company’s balance sheet as deferred revenue.  See Note 3 “Revenue Recognition” in “Notes to Condensed Consolidated Financial Statements”.

This Year-to-Date Report on Form 10-Q contains certain financial information not derived in accordance with GAAP, including customer billings information.  The Company believes this information is useful to investors and other interested parties as customer billings represents all invoiced amounts associated with products shipped during the period reported.  Such information should not be considered as a substitute for any measures derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies.  Reconciliation of this information to the most comparable GAAP measures is included above.

The increase in revenues is primarily attributable to increased billings in the Pharmaceutical ($0.8 million), U.S. Government Contract ($0.7 million), Professional ($0.4 million) and Retail ($0.4 million) markets.  These increases in billings were partially offset by decreased billings in the Home Health Care ($0.1 million) and Core Government ($0.1 million) markets. The increase in the Pharmaceutical market billings is due to the timing of customer orders including resupply orders for existing patient support programs and the launch during the quarter of one of three new patient support programs announced in August and October 2011. The programs include the direct fulfillment of the Sharps Recovery System® to the pharmaceutical manufacturers’ program participants which provides the proper containment, return and treatment of the needles or injection devices utilized in therapy. U.S. Government Contract billings are associated with the Company’s contract with a major U.S. government agency announced in February 2009. The increase in the U.S. Government contract market billings is due to the start of the second option year, which includes a higher payment for increased maintenance service fees than the first option year. The increase in the Professional market was a direct result of the Company’s targeted telemarketing activities, new website and corresponding promotional activities to educate doctors, dentists and veterinarians on the significant cost advantage and the convenience of the Sharps Recovery System™ over the traditional pick-up service. In addition, the Professional market billings increased due to higher distributor network sales to the professional market which were up based on ordering patterns. The increase in the Retail market is primarily due to sales from the initial fill of the Complete Needle™ Collection & Disposal System in the country’s largest drugstore chain and a shift in ordering patterns by retail pharmacies for the 2011 flu shot season over prior year. The decrease in billings in the Home Health Care market was primarily due to timing of sales to home health care related distributors addressing the growing trend of patient volumes in the home health care industry. The level of Core Government market billings reflects the completion of the VA Pilot Program. The VA has assigned an internal representative to evaluate the pilot and what a potential nationwide rollout would entail.

Cost of revenues for the six months ended December 31, 2011 of $8.0 million was 66.8% of revenues.  Cost of revenues for the six months ended December 31, 2010 of $6.8 million was 69.1% of revenue.  The higher gross margin for the six months ended December 31, 2011 of 33.2% (versus 30.9% for the six months ended December 31, 2010) was due to the leverage inherent in the business due to increased sales volume offset by unscheduled maintenance and repairs at the Company’s treatment facility and up-front costs related to the initial rollout of the Complete Needle™ Collection & Disposal System.
 
Selling, general and administrative (“SG&A”) expenses for the six months ended December 31, 2011 of $4.2 million, decreased by $0.5 million, from SG&A expenses of $4.7 million for the six months ended December 31, 2010.  The decrease in SG&A is primarily due to (i) lower compensation and benefit expense including payroll tax of $0.2 million (primarily due to timing of employee hires and terminations), (ii) lower miscellaneous expense of $0.2 million (primarily related lower to recruiting fees and stock-based compensation expense) and (iii) lower professional fees of $0.2 million (primarily due to regulatory and consulting fees, legal fees and other sales-related consulting fees. The decrease was partially offset by increased marketing expense of $0.1 million (primarily due to consulting expenses and timing of new campaigns).
 
During the first quarter of fiscal year 2011, the Company recorded a special charge of $0.6 million on a pre-tax basis, or $0.02 per diluted loss per share, which represents expenses incurred with the retirement of the Company’s former Chief Executive Officer, Dr. Burton Kunik. The special charge consists of (i) severance-related items totaling $0.5 million and (ii) non-cash stock-based compensation expense of $0.1 million (resulting from accelerated vesting of stock option awards). The Company paid Dr. Kunik $0.1 million in September 2010 and $0.4 million in April 2011 related to the expenses noted above.

The Company generated an operating loss of $0.5 million for the six months ended December 31, 2011 compared to an operating loss of $2.4 million for the six months ended December 31, 2010.  The operating margin was (3.9%) for the six months ended December 31, 2011 compared to (24.6%) for the six months ended December 31, 2010. The improvement in operating loss is a result of the higher sales volume as well as strong cost discipline and focused use of resources on targeted markets primarily Retail, Pharmaceutical, Professional and Core Government markets (discussed above).

The Company generated a loss before tax of $0.5 million for the six months ended December 31, 2011 versus a loss before tax of $2.4 million for the six months ended December 31, 2010. The improvement in loss before tax is a result of a lower operating loss (discussed above).

The Company’s effective tax rate for the six months ended December 31, 2011 was 35.2% compared to 33.0% for the six months ended December 31, 2010 and 33.8% for the fiscal year ended June 30, 2011. The effective tax rate for the six months ended December 31, 2011 is higher due to the expected impact of state income taxes as a result of forecasted fiscal year 2012 income.

The Company generated a net loss of $0.3 million for the six months ended December 31, 2011 compared to a net loss of $1.6 million for the six months ended December 31, 2010.  The improvement is result of a lower operating loss (discussed above).

The Company reported diluted loss per share of $0.02 for the six months ended December 31, 2011 versus diluted loss per share of ($0.11) for the six months ended December 31, 2010.  The improvement in diluted earnings per share is a result of a lower net loss (discussed above).



PROSPECTS FOR THE FUTURE

The Company continues to take advantage of the many opportunities in the markets served as professional offices, retail pharmacies, communities, consumers, pharmaceutical manufacturers, government agencies, health care facilities, individual self-injectors and commercial organizations become more aware of the need for the proper treatment of medical sharps waste, used healthcare materials and unused dispensed medications as well as alternatives to traditional methods of disposal.

Recent data from the Human Capital Management Services Group indicates that the number of used needles improperly disposed of outside the large healthcare setting and into the solid waste system has tripled over the past ten years to 7.8 billion each year and the number of self-injectors in the country has increased to 13.5 million over the same period.  The Company estimates that it would require over 80 million Sharps Recovery System™ (formerly Sharps Disposal by Mail System®) products to properly dispose of all such syringes, which would equate to a market opportunity of over $2 billion.

There are an estimated 800,000 doctors, dentists, veterinarians, clinics, tattoo parlors and other businesses in the country that generate smaller quantities of medical waste, including used syringes. These offices and facilities, which must demonstrate proper management of their medical waste, comprise a market opportunity of approximately $600 million, based on estimates of using our solution offerings rather than the traditional pick-up service in what we characterize as a regulated market.

Additionally, an estimated 40% of the four billion dispensed medication prescriptions go unused every year in the United States generating an estimated 200 million pounds of unused medication waste. The Company estimated the market opportunity for the proper recovery and management of the unused medications to be at least $1 billion per year.

The Company continues to develop new solution offerings including the Complete Needle™ Collection and Disposal System (designed for the traditional under-served home self-injector), the TakeAway line of products for unused medications (including TakeAway Environmental Return System™ ), the Medical/Professional TakeAway Recovery System™ and the RX TakeAway Recovery and Reporting System which offers the collection, storage, audit, witnessed treatment and documentation of unused medications such as flu vaccines, Tamiflu, and Relenza. These innovative product and service offerings allow us to gain further sales from existing customers as well as gain new customers who have a need for more comprehensive products.   The Company continues to develop solution offerings designed to facilitate the proper and cost effective solutions for management of medical waste, used healthcare materials and unused dispensed medication to better serve our customers and the environment. The Company believes its future growth will be driven by, among other items: (i) the convergence of issues regarding the environment, the cost of health care and changes in our health care delivery system and cost-savings initiatives which influence the decision process of our customers, (ii) the effects of the Company’s extensive multi-layered marketing and awareness efforts and (iii) the Company’s leadership position in the development and sales of products and services designed for the proper and cost effective solutions for management of medical waste, used healthcare materials and unused dispensed.

In August 2011, the Company introduced the Complete Needle™ Collection and Disposal System which is focused on the traditional under-served home self-injector required to regularly use needles or syringes for their health and well-being, such as people with diabetes. The Complete Needle™ Collection and Disposal System is actually two offerings in one.  First, the product provides the individual self-injector with a reasonably priced containment solution designed to protect self-injectors and their family members.  Second, the product includes an optional disposal feature utilizing the USPS designed to protect the individual’s community, solid waste workers and the environment. The solution offers significant convenience as it utilizes the same delivery channel, the retail pharmacy, that the self-injector typically uses to obtain medications, for example, insulin, and needles or syringes. The solution is also designed to enhance the interaction between the pharmacist and the individual thereby creating counseling opportunities and possibly better treatment outcomes.

The Company continues to add full-service, patient support programs with major pharmaceutical manufacturers whereby we provide a customized Sharps Recovery System™ (formerly Sharps Disposal by Mail System®) along with fulfillment, inventory management, storage and data services, as well as provide critical patient usage data that assists the manufacturers in assessing drug effectiveness and compliance.

In January 2010, the Company announced a pilot program with the United States Department of Veterans Affairs (“VA”). The program was launched within the VA Capitol Health Care Network (“Veterans Integrated Service Network 5” or “VISN 5”), which provided quality health care for eligible veterans in Maryland and portions of Virginia, West Virginia, and Pennsylvania, as well as the District of Columbia.  The pilot allowed each of the participating medical centers within the VISN 5 region, both inpatient and outpatient, to provide the Sharps Recovery System™ (formerly known as the Sharps® Disposal By Mail System®) and the TakeAway Environmental Return System™ solutions to their patients.  Since its original launch, the pilot program expanded to include eight VISN’s (encompassing twenty-two states plus the District of Columbia). There are a total of twenty-three VISN’s in the VA System. The VISN network is part of the Veterans Health Administration which encompasses the largest integrated health care system in the United States, consisting of 153 medical centers, in addition to numerous community based outpatient clinics, community living centers and Vet Centers. Together these health care facilities provide comprehensive care to over 5.5 million Veterans each year. The VA Pilot, which was completed in the first quarter of fiscal year 2012, was conducted in 22 states plus the District of Columbia. The VA has assigned an internal representative to evaluate the pilot and what a potential nationwide rollout would entail.

In February 2009, the Company launched Sharps®MWMS™, a Medical Waste Management System (“MWMS”), which is a comprehensive medical waste and dispensed medication solution which includes an array of products and services necessary to effectively collect, store and treat medical waste and unused dispensed medication outside of the hospital or large health care facility setting.
 
The successful execution of the U.S. government contract program from the product build out in calendar year 2009 through the end of the second option year for maintenance services demonstrates the attractiveness of our integrated, full-service system that enables government agencies and commercial organizations to completely outsource the planning and execution of their emergency preparedness and disaster relief planning as it relates to medical waste handling and rapid response capabilities.

The Company believes the pace of regulation of sharps and unused dispensed medications disposal is gaining momentum at both the state and federal level. In December 2004, the U. S. Environmental Protection Agency (“EPA”) issued its new guidelines for the proper disposal of medical sharps, revising the previous guidance that advised patients to dispose of used syringes in the trash (see http://www.epa.gov/wastes/nonhaz/industrial/medical/med-govt.pdf).  Additionally, in July 2006 both the states of California and Massachusetts passed legislation designed to mandate appropriate disposal of sharps waste necessary to protect the general public and workers from potential exposure to contagious diseases and health and safety risks. In April 2011, the U.S. Senate re-introduced a bill (S.725) which, if enacted, would provide for Medicare reimbursement, under part D, for the safe and effective disposal of used needles and syringes.  To protect citizens and waste workers from needle stick injuries, eighteen states and the District of Columbia (covering 43% of the U.S. population) restrict or have introduced legislation to restrict discarding used sharps into household trash and twenty-nine states and the District of Columbia (covering 65% of the U.S. population) have enacted or introduced legislation to regulate the disposal of consumer unused medications to reduce pollution of the environment.  As state and federal enforcement of these statutes increases, more companies will turn to solutions such as ours to help manage their medical waste and regulatory compliance. The Company believes it is well positioned to benefit given our strict adherence to established standards and extensive documentation and records.

The Company’s growth strategies are focused on the Retail, Pharmaceutical, Professional and Core Government markets. The Company also serves the Home Health Care, Assisted Living/Hospitality and Other markets. The Pharmaceutical market billings for the six months ended December 31, 2011 increased over $0.8 million over the prior year as a result of timing of customer orders including resupply orders for existing patient support programs and the launch during the period of one of three new patient support programs announced in August and October 2011. The combined programs are expected to generate annual revenue in excess of $3.0 million once fully implemented after a six- to nine-month implementation period.

In October 2011, the Company announced the promotional program being offered for the Complete Needle™ Collection & Disposal System in support of National Diabetes Month sponsored by a leading global insulin manufacturer and the nation’s largest drugstore chain. Within this promotion program, the pharmaceutical manufacturer and the retail pharmacy in effect purchased the solutions from the Company and provided it at no cost to the user through rebates and redemption codes printed at the register. The Company believes this could serve as a model program for the country and that larger participation and sponsorship of the offering by other retail channels as well as additional drug and ancillary product manufacturers could follow. The Company also believes that similar sponsorship could be available for its TakeAway line of products for unused medications.

The Company currently has a cash balance of $18.3 million and no debt as of December 31, 2011. Under the Company’s Credit Agreement (“the Credit Agreement”) with Wells Fargo, National Association, the Company had no outstanding borrowings, $106 thousand in letters of credit outstanding, and $4.9 million of credit available.

RECENT DEVELOPMENTS

 
On January 13, 2012, the Company was notified by a department of the U. S. Government, acting on behalf of the Division of Strategic National Stockpile (“DSNS”) that the maintenance contract will not be renewed for the third option year (beginning February 1, 2012) and that the contract would be terminated effective January 31, 2012. This non-renewal was preceded by a letter dated December 2, 2011 advising the Company of the U.S. Government’s intent to exercise the third option year.
 
 
In February 2009, the Company signed a five year contract (one year, plus four option years) with a major U.S. government agency for a $40 million program to provide our comprehensive Medical Waste Management System™, or Sharps®MWMS™, which is a rapid-deployment solution offering designed to provide medical waste collection, storage and treatment in the event of natural disasters, pandemics, man-made disasters, or other national emergencies.  Sharps®MWMS™ is unique in that the solution also offers warehousing, inventory management, training, data and other services necessary to provide a comprehensive solution. We received a purchase order for $28.5 million ($6.0 million of which was recognized in fiscal year 2009, and $22.5 million was recognized in the first half of fiscal year 2010).  In January 2010, the Company was awarded the first option year (ending January 31, 2011) valued at approximately $1.6 million which was recognized from February 1, 2010 through January 31, 2011.  In January 2011, we were awarded the second option year (ending January 31, 2012) valued at approximately $3.0 million and is to be recognized from February 1, 2011 through January 31, 2012. The remaining two option years were expected to be approximately $3.0 million per contract year.
 
 
Although not stated in the notice provided by the U.S. Government, the Company believes the action is part of a budget reduction program being implemented by the DSNS.
 
LIQUIDITY AND CAPITAL RESOURCES

Cash Flow

Cash and cash equivalents increased by less than $0.1 million to $18.3 million at December 31, 2011 from $18.3 million at June 30, 2011. The increase in cash and cash equivalents is primarily due to the timing of collections from orders related to billings in the current quarter and fourth quarter of fiscal year 2011, offset somewhat by the inventory buildup in the current quarter (discussed below).

Accounts receivable decreased by $0.5 million to $2.6 million at December 31, 2011 from $3.1 million at June 30, 2011. The decrease is due to higher billings in June 2011 which were collected during the first quarter of fiscal year of 2012.

Inventory increased by $0.7 million to $2.5 million at December 31, 2011 from $1.8 million at June 30, 2011.  The increase in inventory is due to buildup of new product lines in the current quarter in preparation for new programs.

Property, plant and equipment, net decreased by $357 thousand to $5.0 million at December 31, 2011 from $5.3 million at June 30, 2011.  The decrease in property and equipment is related to depreciation expense of $533 thousand, partially offset by capital expenditures of $189 thousand.The capital expenditures are attributable primarily to the purchase of, (i) computer equipment, new website project and custom software programming of $137 thousand, (ii) manufacturing and assembly equipment including molds, dies and printing plates of $22 thousand primarily for new product development, (iii) treatment facility improvement of $17 thousand and (iv) general leasehold improvements for the warehouse and office equipment of $13 thousand.

Stockholders’ equity increased by $0.1 million to $26.0 million at December 31, 2011 from $25.9 million at June 30, 2011.  This increase is primarily attributable to (i) the effect on equity (credit) of non-cash stock based award expense of $0.4 million and (ii) the excess tax benefits from stock-based award activity of $12 thousand. The impact was partially offset by a net loss for the six months ended December 31, 2011 of $0.3 million.

Off -Balance Sheet Arrangements

The Company entered into certain off-balance sheet arrangements in the ordinary course of business that result in risks not directly reflected in our balance sheets. The Company’s most significant off-balance sheet transactions include commitments associated with non-cancelable operating leases. The Company has other off-balance sheet obligations involving letters of credit.

The Company entered into non-cancelable operating leases for certain of our facility, vehicle and equipment needs. These leases allow us to conserve cash by paying a monthly lease rental fee for use of facilities, vehicles and equipment rather than purchasing them. At the end of the lease, the Company has no further obligation to the lessor. If we decide to cancel or terminate a lease before the end of its term, we would typically owe the lessor the remaining lease payments under the term of the lease.

Credit Facility

The Company’s Credit Agreement with Wells Fargo Bank, National Association provides for a two-year, $5.0 million line of credit facility, the proceeds of which may be utilized for: (i) working capital, (ii) capital expenditures, (iii) letters of credit (up to $500,000), (iv) acquisitions (up to $1,000,000) and (v) general corporate purposes. As of December 31, 2011, the Company had no outstanding borrowings, $106 thousand in letters of credit outstanding, and $4.9 million of credit available.

Indebtedness under the Credit Agreement is secured by substantially all of the Company’s assets. Borrowings bear interest at either (i) a fluctuating rate per annum equal to LIBOR plus a margin of 250 basis points or (ii) at the Company’s option, a fixed rate for a 30, 60, or 90 day period set at the option date’s LIBOR plus a margin of 250 basis points. Any outstanding revolving loans, and accrued and unpaid interest, will be due and payable on July 15, 2012, the maturity date of the Credit Agreement. The Company pays a fee of 0.2% per annum on the unused amount of the line of credit. The Company estimates that the interest rate applicable to the borrowings under the Credit Agreement would be approximately 3.1% as of December 31, 2011.

The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a minimum level of tangible net worth of $21 million and not exceed a ratio of liabilities to tangible net worth of 1.0 to 1.0. As of December 31, 2011, the Company is in compliance with all financial covenants. The Credit Agreement also contains customary events of default. Upon the occurrence of an event of default that remains uncured after any applicable cure period, the lenders’ commitment to make further loans may terminate and the Company may be required to make immediate repayment of all indebtedness to the lenders. The Credit Agreement expires on July 15, 2012.


Management believes that the Company’s current cash resources (cash on hand and cash generated from operations) along with its $5.0 million line of credit with Wells Fargo Bank will be sufficient to fund operations for the twelve months ending December 31, 2012.

CRITICAL ACCOUNTING ESTIMATES

The Company recognizes revenue from product sales when goods are shipped or delivered, and title and risk of loss pass to the customer except for those sales via multiple-deliverable arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.

Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served.

The Company recognizes revenue in accordance with guidance on revenue recognition of multiple-deliverable revenue arrangements. On July 1, 2010, the Company adopted ASU No. 2009-13 which further clarified guidance on revenue recognition for multiple-deliverable revenue arrangements, changing the way the Company allocates arrangement consideration to the separate units of accounting.  Under this guidance, certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ (formerly the Sharps Disposal by Mail Systems®) and various TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation  and (3) treatment service.

Prior to July 1, 2010, the individual fair value of the transportation and treatment services were determined by the sales price of the service offered by third parties, with the fair value of the compliance and container being the residual value.  Beginning July 1, 2010, under the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting.  The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price.  Because an estimated selling price must be set for each unit, the residual method used previously by the Company to allocate consideration to the compliance and container system is no longer allowed.  The selling price for the transportation revenue and the treatment revenue, which utilizes third party evidence, did not change from the prior method.  The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities.
 
Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership.  Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s facility.  The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s facility. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container.  Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed.  The current and long-term portions of deferred revenues are determined through regression analysis and historical trends.  Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned.  Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.

RECENTLY ISSUED ACCOUNTING STANDARDS

There are no recently issued accounting pronouncements that impact the Company’s condensed consolidated financial statements as of December 31, 2011.




The Company does not have exposure to significant financial market risk including commodity price risk, foreign currency exchange risk or interest rate risk. Management does not use derivative instruments. The Company has limited exposure to changes in interest rates due to its lack of indebtedness.  The Company maintains a credit agreement under which we may borrow funds in the future. Currently, the Company does not foresee any borrowing needs.


Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures”, as such term is defined in Rule 13a-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including, the Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”) as appropriate, to allow timely decisions regarding required disclosure.

As of December 31, 2011, the Company conducted an evaluation (the “Evaluation”), under the supervision and with the participation of the CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls”), pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act.  Based upon this Evaluation, the CEO and CFO concluded that our Disclosure Controls were effective as of December 31, 2011.

Changes in Internal Control over Financial Reporting

During the quarter ended December 31, 2011, there were no changes in the Company’s internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act), that have materially affected, or are reasonably likely to materially affect the Company’s internal control over financial reporting.

CEO and CFO Certifications

Appearing immediately following the Signatures section of this report are certifications of the CEO and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This Item of this Quarterly Report on Form 10-Q, which you are currently reading, is the information concerning the Evaluation referred to in the Section 302 Certification and this information should be read in conjunction  with the Section 302 Certifications for a more complete understanding of the topics presented.



The Company is involved in legal proceedings and litigation in the ordinary course of business.  In the opinion of management, the outcome of such matters will not have a material adverse effect on the Company’s consolidated financial position or consolidated results of operations.


Refer to Item 1A. Risk Factors in the Company’s annual report on Form 10-K for the year ended June 30, 2011 for the Company’s risk factors.  During the quarter ended December 31, 2011, there have been no changes to the Company’s risk factors.





(a)
Exhibits:
   
31.1
Certification of Chief Executive Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)
   
31.2  
Certification of Chief Financial Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)
   
32.1
Certification of Chief Executive Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)
   
32.2
Certification of Chief Financial Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)
   
101.INS
XBRL Instance Document (filed herewith)
   
101.SCH
XBRL Taxonomy Extension Schema Document (filed herewith)
   
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith)
   
101.DEF
XBRL Taxonomy Extension Linkbase Document (filed herewith)
   
101.LAB
XBRL Taxonomy Extension Label Linkbase Document (filed herewith)
   
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith)


ITEMS 2, 3, AND 5 ARE NOT APPLICABLE AND HAVE BEEN OMITTED.








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
REGISTRANT:
 
SHARPS COMPLIANCE CORP.
   
Dated: February 1, 2012
By: /s/ DAVID P. TUSA 
 
David P. Tusa
 
Chief Executive Officer and President
 
(Principal Executive Officer)

Dated: February 1, 2012
By: /s/ DIANA P. DIAZ 
 
Diana P. Diaz
 
Vice President and Chief Financial Officer
 
(Principal Financial and Accounting Officer)



EX-31.1 2 exhibit31_1.htm EXHIBIT 31.1 exhibit31_1.htm
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
IN ACCORDANCE WITH SECTION 302 OF THE SARBANES-OXLEY ACT

I, David P. Tusa, certify that:

1.  
I have reviewed this quarterly report on Form 10-Q of Sharps Compliance Corp.;

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)  
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: February 1, 2012
/s/David P. Tusa
 
Chief Executive Officer and President
 
(Principal Executive Officer)



EX-31.2 3 exhibit31_2.htm EXHIBIT 31.2 exhibit31_2.htm
Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
IN ACCORDANCE WITH SECTION 302 OF THE SARBANES-OXLEY ACT

I, Diana P. Diaz, certify that:

1.  
I have reviewed this quarterly report on Form 10-Q of Sharps Compliance Corp.;

2.  
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.  
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)  
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.  
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
 
(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: February 1, 2012
/s/Diana P. Diaz
 
Vice President and Chief Financial Officer
 
(Principal Financial and Accounting Officer)


EX-32.1 4 exhibit32_1.htm EXHIBIT 32.1 exhibit32_1.htm
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
IN ACCORDANCE WITH SECTION 906 OF THE SARBANES-OXLEY ACT

In connection with the quarterly report of Sharps Compliance Corp. (the “Company”) on Form 10-Q for the three and six months ended December 31, 2011, as filed with the Securities and Exchange Commission on the date hereof, I, David P. Tusa, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1)  
The Form 10-Q report for the three and six months ended December 31, 2011, filed with the Securities and Exchange Commission on February 1, 2012 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  
The information contained in the Form 10-Q report for the three and six months ended December 31, 2011 fairly presents, in all material respects, the financial condition and results of operations of Sharps Compliance Corp.

Date: February 1, 2012
/s/David P. Tusa
 
Chief Executive Officer and President


EX-32.2 5 exhibit32_2.htm EXHIBIT 32.2 exhibit32_2.htm
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER
IN ACCORDANCE WITH SECTION 906 OF THE SARBANES-OXLEY ACT

In connection with the quarterly report of Sharps Compliance Corp. (the “Company”) on Form 10-Q for the three and six months ended December 31, 2011, as filed with the Securities and Exchange Commission on the date hereof, I, Diana P. Diaz, Vice President and Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

(1)  
The Form 10-Q report for the three and six months ended December 31, 2011, filed with the Securities and Exchange Commission on February 1, 2012 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)  
The information contained in the Form 10-Q report for the three and six months ended December 31, 2011 fairly presents, in all material respects, the financial condition and results of operations of Sharps Compliance Corp.

Date: February 1, 2012
/s/Diana P. Diaz
 
Vice President and Chief Financial Officer


EX-101.INS 6 smed-20111231.xml SMED 20111231.XML 0000898770 2011-12-31 0000898770 2011-06-30 0000898770 2011-10-01 2011-12-31 0000898770 2010-10-01 2010-12-31 0000898770 2011-07-01 2011-12-31 0000898770 2010-07-01 2010-12-31 0000898770 us-gaap:CommonStockMember 2011-07-01 2011-12-31 0000898770 us-gaap:AdditionalPaidInCapitalMember 2011-07-01 2011-12-31 0000898770 us-gaap:RetainedEarningsMember 2011-07-01 2011-12-31 0000898770 us-gaap:CommonStockMember 2010-06-30 0000898770 us-gaap:AdditionalPaidInCapitalMember 2010-06-30 0000898770 us-gaap:RetainedEarningsMember 2010-06-30 0000898770 2010-06-30 0000898770 us-gaap:CommonStockMember 2010-07-01 2011-06-30 0000898770 us-gaap:AdditionalPaidInCapitalMember 2010-07-01 2011-06-30 0000898770 us-gaap:RetainedEarningsMember 2010-07-01 2011-06-30 0000898770 2010-07-01 2011-06-30 0000898770 us-gaap:CommonStockMember 2011-06-30 0000898770 us-gaap:AdditionalPaidInCapitalMember 2011-06-30 0000898770 us-gaap:RetainedEarningsMember 2011-06-30 0000898770 us-gaap:CommonStockMember 2011-12-31 0000898770 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000898770 us-gaap:RetainedEarningsMember 2011-12-31 0000898770 2010-12-31 0000898770 2012-01-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares 2600000 3065000 -242000 -227000 22003000 21602000 -24000 -26000 0.00 -0.05 -0.02 -0.11 18343000 18280000 18068000 17847000 156000 861000 -465000 -19000 713000 383000 60000 441000 20000 20000 15096291 15053316 15096291 15053316 14891754 0 0 0 15053316 0 0 15096291 0 0 151000 151000 4065000 3385000 7989000 6806000 2000 -981000 0 -1342000 4297000 3949000 <div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The Company's Credit Agreement with Wells Fargo Bank, National Association provides for a two-year, $5.0 million line of credit facility, the proceeds of which may be utilized for: (i) working capital, (ii) capital expenditures, (iii) letters of credit (up to $500,000), (iv) acquisitions (up to $1,000,000) and (v) general corporate purposes. As of December 31, 2011, the Company had no outstanding borrowings, $106 thousand in letters of credit outstanding, and $4.9 million of credit available.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Indebtedness under the Credit Agreement is secured by substantially all of the Company's assets. Borrowings bear interest at either (i) a fluctuating rate per annum equal to LIBOR plus a margin of 250 basis points or (ii) at the Company's option, a fixed rate for a 30, 60, or 90 day period set at the option date's LIBOR plus a margin of 250 basis points. Any outstanding revolving loans, and accrued and unpaid interest, will be due and payable on July 15, 2012, the maturity date of the Credit Agreement. The Company pays a fee of 0.2% per annum on the unused amount of the line of credit. The Company estimates that the interest rate applicable to the borrowings under the Credit Agreement would be approximately 3.1% as of December 31, 2011.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a minimum level of tangible net worth of $21 million and not exceed a ratio of liabilities to tangible net worth of 1.0 to 1.0. As of December 31, 2011, the Company is in compliance with all financial covenants. The Credit Agreement also contains customary events of default. Upon the occurrence of an event of default that remains uncured after any applicable cure period, the lenders' commitment to make further loans may terminate and the Company may be required to make immediate repayment of all indebtedness to the lenders. The Credit Agreement expires on July 15, 2012.</font></div></div> 13000 603000 -161000 552000 233000 203000 1773000 1724000 329000 401000 116000 87000 223000 176000 0.00 -0.05 -0.02 -0.11 376000 507000 -13000 0 <div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 5 - INCOME TAXES</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The Company's effective tax rate for the six months ended December 31, 2011 was 35.2% compared to 33.0% for the six months ended December 31, 2010 and 33.8% for the fiscal year ended June 30, 2011.&#160; The effective tax rate for the six months ended December 31, 2011 is higher due the expected impact of state income taxes as a result of forecasted fiscal year 2012 income.</font></div><div style="display: block; text-indent: 0pt;"><br /></div></div> 376000 325000 2483000 1770000 4866000 4733000 30835000 30598000 25000 966000 -254000 -332000 292000 -855000 28000 -807000 -297000 -1604000 0 0 -2975000 -2975000 0 0 -297000 63000 -221000 9000 15000 6000 28000 34000 -1200000 -464000 -2422000 13000 2000 4993000 5350000 65000 84000 189000 248000 3815000 4112000 6212000 4611000 11955000 9844000 <div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 10 &#8211; INVENTORY</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The components of inventory are as follows (in thousands):</font></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><br />&#160;</div><div align="center"><table cellpadding="0" cellspacing="0" width="50%" style="font-size: 10pt; font-family: times new roman;"><tr><td valign="bottom" width="35%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="16%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="16%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">June 30,</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="35%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="16%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="16%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="35%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="16%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(Unaudited)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="16%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="35%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Raw materials</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="15%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">1,271</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="15%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">790</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="35%" style="padding-bottom: 2px;"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Finished goods</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="15%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">1,212</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="15%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">980</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="35%" style="padding-bottom: 4px;"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Total</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="15%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">2,483</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 4px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 4px double; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="15%" style="border-bottom: black 4px double; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">1,770</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 4px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr></table></div></div> 1997000 2339000 4207000 4714000 <div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">REVENUE RECOGNITION</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The Company recognizes revenue from product sales when goods are shipped or delivered, and title and risk of loss pass to the customer except for those sales via multiple-deliverable arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served.</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div style="display: block; text-indent: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The Company recognizes revenue in accordance with guidance on revenue recognition of multiple-deliverable revenue arrangements. On July 1, 2010, the Company adopted ASU No. 2009-13 which further clarified guidance on revenue recognition for multiple-deliverable revenue arrangements, changing the way the Company allocates arrangement consideration to the separate units of accounting.&#160;&#160;Under this guidance, certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System&#8482; (formerly the Sharps<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#160;</font>Disposal by Mail Systems<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font>) and various TakeAway Environmental Return Systems&#8482; referred to as &#8220;Mailbacks&#8221; and Sharps<font style="display: inline; font-size: 70%; vertical-align: text-top;">&#174;</font> Pump and Asset Return Boxes, referred to as &#8220;Pump Returns&#8221;) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation&#160;&#160;and (3) treatment service.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Prior to July 1, 2010, the individual fair value of the transportation and treatment services were determined by the sales price of the service offered by third parties, with the fair value of the compliance and container being the residual value.&#160;&#160;Beginning July 1, 2010, under the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting.&#160;&#160;The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price.&#160;&#160;Because an estimated selling price must be set for each unit, the residual method used previously by the Company to allocate consideration to the compliance and container system is no longer allowed.&#160;&#160;The selling price for the transportation revenue and the treatment revenue, which utilizes third party evidence, did not change from the prior method.&#160;&#160;The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership.&#160;&#160;Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company's facility. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company's facility. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container.&#160;&#160;Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed.&#160;&#160;The current and long-term portions of deferred revenues are determined through regression analysis and historical trends.&#160;&#160;Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned.&#160;&#160;Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">ACCOUNTS RECEIVABLE</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Accounts receivable consist primarily of amounts due to us from our normal business activities.&#160;&#160;Accounts receivable balances are determined to be </font><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">delinquent when the amount is past due based on the contractual terms with the customer.&#160;&#160;The Company maintains an allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past collection history and specific risks identified among uncollected accounts.&#160;&#160;Accounts receivable are charged to the allowance for doubtful accounts when the Company has determined that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.</font></div></div> <div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 9 - EQUITY TRANSACTIONS</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">During the three and six months ended December 31, 2011 and 2010, stock options to purchase shares of the Company's common stock were exercised as follows: </font></div><div style="display: block; text-indent: 0pt;"><br /></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="center"><table cellpadding="0" cellspacing="0" width="90%" style="font-size: 10pt; font-family: times new roman;"><tr><td valign="bottom" width="52%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Three-Months Ended</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Six-Months Ended</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2010</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2010</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(Unaudited)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(Unaudited)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Options exercised</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">14,103</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">2,000</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Proceeds (in thousands)</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">13</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">2</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Average exercise price per share</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.95</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.84</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">As of December 31, 2011, there was $991 thousand of stock option and restricted stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 2.4 years.</font></div></div> 12000 964000 24576000 24175000 15404 14920 15071 14914 15077 14920 15071 14914 30835000 30598000 9000 15000 6000 28000 240000 383000 890000 748000 <div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 7 &#8211; STOCK-BASED COMPENSATION</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity grant).&#160;&#160;Total stock-based compensation for the three months ended December 31, 2011 and 2010 was $257 thousand ($18 thousand included in cost of revenues and $239 thousand included in general and administrative expense in the Company's condensed consolidated statement of operations) and $292 thousand ($25 thousand included in cost of revenues and $267 thousand included in general and administrative expense in the Company's condensed consolidated statement of operations), respectively. Total stock-based compensation for the six months ended December 31, 2011 and 2010 was $376 thousand ($38 thousand included in cost of revenues and $338 thousand included in general and administrative expense in the Company's condensed consolidated statement of operations) and $507 thousand ($45 thousand included in cost of revenues and $462 thousand included in general and administrative expense in the Company's condensed consolidated statement of operations), respectively.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Reductions in taxes payable resulting from tax deductions that exceed the recognized tax benefit associated with compensation expense (excess tax benefits) are classified as financing cash flows and as an increase to additional paid in capital. The Company's excess tax benefits included in its cash flows from financing activities for the six months ended December 31, 2011 and 2010 was $12 thousand and $964 thousand, respectively.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">In conjunction with the retirement and separation agreement of Dr. Burton Kunik, effective September 30, 2010, the Company recognized an additional $73 thousand in stock-based compensation expense which is included in the Special Charge on the accompanying statement of operations for the six months ended December 31, 2010.</font></div><div style="display: block; text-indent: 0pt;"><br /></div></div> <div><div style="display: block; text-indent: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 11 &#8211; FAIR VALUE OF FINANCIAL INSTRUMENTS</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, not to be materially different from their carrying values at year-end due to their short-term nature.</font></div></div> 12000 964000 -23000 99000 43000 -1185000 -458000 -2394000 0.01 0.01 25969000 25865000 149000 19705000 7087000 26941000 151000 21602000 4112000 151000 22003000 3815000 15000 -378000 -161000 -790000 1000 -1000 0 0 0 0 0 0 1000 48000 0 49000 0 13000 0 13000 99062 0 0 0 28872 0 0 0 62500 0 0 0 14103 0 0 0 6178000 5811000 12419000 12266000 <div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;"><font style="display: inline; font-weight: bold;">NOTE 8 - EARNINGS PER SHARE</font></font></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;">&#160;</div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Earnings per share are measured at two levels: basic per share and diluted per share. Basic per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted per share is computed by dividing net income by the weighted average number of common shares after considering the additional dilution related to common stock options and restricted stock. In computing diluted earnings per share, the outstanding common stock options are considered dilutive using the treasury stock method. Vested restricted shares are included in basic common shares outstanding, and unvested restricted shares are included in the diluted common shares outstanding, if the effect is dilutive.</font></div><div style="display: block; text-indent: 0pt;">&#160;</div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="center"><table cellpadding="0" cellspacing="0" width="90%" style="font-size: 10pt; font-family: times new roman;"><tr><td valign="bottom" width="52%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Three-Months Ended</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Six-Months Ended</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">December 31,</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2010</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2011</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%" style="border-bottom: black 2px solid; text-align: center;"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; text-align: center;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2010</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(Unaudited)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="6" valign="bottom" width="22%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(Unaudited)</font></div></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td colspan="2" valign="bottom" width="10%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Net income (loss), as reported</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">28</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(807</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(297</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(1,604</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Weighted average common shares outstanding</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">15,077</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">14,920</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">15,071</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">14,914</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Effect of dilutive stock options</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">327</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%" style="padding-bottom: 2px;"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Weighted average diluted common shares outstanding</font></div></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">15,404</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">14,920</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">15,071</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="border-bottom: black 2px solid; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="border-bottom: black 2px solid; text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">14,914</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="padding-bottom: 2px; text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Net income (loss) per common share</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;&#160;&#160;&#160;Basic</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.00</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(0.05</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(0.02</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(0.11</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;&#160;&#160;&#160;Diluted</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.00</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(0.05</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(0.02</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(0.11</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160; </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Employee stock options excluded from computation</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="white"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;of dilutive income per share amounts because their</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr><tr bgcolor="#cceeff"><td valign="bottom" width="52%"><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;&#160;&#160;effect would be anti-dilutive</font></div></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">513</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">412</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">538</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td align="right" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td><td valign="bottom" width="9%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">412</font></td><td nowrap="nowrap" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">&#160;</font></td></tr></table></div></div> 548000 499000 <div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 1 - ORGANIZATION AND BACKGROUND</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com, Inc. (&#8220;Sharps e-Tools&#8221;), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.) and Sharps Safety, Inc. (collectively, &#8220;Sharps&#8221;, &#8220;We&#8221; or the&#160;&#160;&#8220;Company&#8221;).&#160;&#160;All significant intercompany accounts and transactions have been eliminated upon consolidation.</font></div></div> 1193000 965000 1331000 1260000 0 871000 0 871000 0 376000 0 376000 <div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 4 &#8211; RECENTLY ISSUED ACCOUNTING STANDARDS</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">There are no recently issued accounting pronouncements that impact the Company's condensed consolidated financial statements as of December 31, 2011.</font></div></div> 0 979000 0 979000 0 12000 0 12000 <div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: Times New Roman;">NOTE 2 - BASIS OF PRESENTATION</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under accounting principles generally accepted in the United States of America for complete financial statements.&#160;&#160;In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of December 31, 2011, the results of its operations and cash flows for the three and six months ended December 31, 2011 and 2010 and stockholders' equity for the year ended June 30, 2011 and six months ended December 31, 2011. The results of operations for the three and six months ended December 31, 2011 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2012.&#160;&#160;These unaudited condensed consolidated financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended June 30, 2011.</font></div></div> false --06-30 2011-12-31 No No Yes Accelerated Filer 52800000 SHARPS COMPLIANCE CORP 0000898770 15096291 2012 Q2 10-Q 917000 857000 0 0 0 570000 EX-101.SCH 7 smed-20111231.xsd SMED 20111231.XSD 001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 001010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 006010 - Disclosure - ORGANIZATION AND BACKGROUND link:presentationLink link:calculationLink link:definitionLink 006020 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 006030 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 006040 - Disclosure - RECENTLY ISSUED ACCOUNTING STANDARDS link:presentationLink link:calculationLink link:definitionLink 006050 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 006060 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 006070 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 006080 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 006090 - Disclosure - EQUITY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 006100 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 006110 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 000990 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 smed-20111231_cal.xml SMED 20111231_CAL.XML EX-101.DEF 9 smed-20111231_def.xml SMED 20111231_DEF.XML EX-101.LAB 10 smed-20111231_lab.xml SMED 20111231_LAB.XML Accounts receivable, net of allowance for doubtful accounts of $24 and $26, respectively INTANGIBLE ASSETS, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Additional paid-in capital Accounts receivable, allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Cash and cash equivalents CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period Cash and Cash Equivalents, at Carrying Value Increase in accounts payable and accrued liabilities Decrease in accounts receivable Increase (Decrease) in Accounts Receivable Increase in inventory Increase (Decrease) in Inventories Increase in prepaid and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Changes in operating assets and liabilities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, shares outstanding (in shares) Balances (in shares) Balances (in shares) Common Stock, Shares, Outstanding Common stock, $0.01 par value per share; 20,000 shares authorized; 15,096 and 15,053 shares issued and outstanding, respectively Cost of revenues Current TOTAL CURRENT LIABILITIES Liabilities, Current CURRENT LIABILITIES NOTES PAYABLE AND LONG-TERM DEBT Debt Disclosure [Text Block] Deferred Deferred tax (benefit) expense Deferred income taxes Deferred revenue LONG-TERM DEFERRED REVENUE Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Diluted (in dollars per share) Earnings Per Share, Diluted Stock-based compensation expense Loss on disposal of property, plant and equipment Gain (Loss) on Disposition of Assets CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) [Abstract] INCOME TAXES Income Tax Disclosure [Text Block] INTANGIBLE ASSETS, net of accumulated amortization of $242 and $227, respectively Inventory TOTAL LIABILITIES Liabilities TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY NET CASH PROVIDED BY FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities CASH FLOWS FROM FINANCING ACTIVITIES NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM INVESTING ACTIVITIES NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM OPERATING ACTIVITIES NET INCOME (LOSS) Net Loss Net loss NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) RECENTLY ISSUED ACCOUNTING STANDARDS [Abstract] TOTAL OTHER INCOME Nonoperating Income (Expense) OTHER INCOME OPERATING INCOME (LOSS) Operating Income (Loss) Proceeds from exercise of stock options PROPERTY, PLANT AND EQUIPMENT, net Additions to intangible assets Payments to Acquire Intangible Assets Purchase of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Retained earnings REVENUES INVENTORY Inventory Disclosure [Text Block] Selling, general and administrative SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) [Abstract] CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) [Abstract] STOCKHOLDERS' EQUITY EQUITY TRANSACTIONS [Abstract] EQUITY TRANSACTIONS Stockholders' Equity Note Disclosure [Text Block] Excess tax benefits from stock-based award activity TOTAL CURRENT ASSETS Assets, Current CURRENT ASSETS Diluted (in shares) Basic (in shares) Common Stock [Member] TOTAL ASSETS Assets Other income OTHER LONG TERM LIABILITIES DEFERRED INCOME TAXES, non-current STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Statement [Table] ASSETS Statement [Line Items] FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Excess tax benefits from stock-based award activity Excess Tax Benefit from Share-based Compensation, Operating Activities (Decrease) increase in deferred revenue NET INCOME (LOSS) PER COMMON SHARE EARNINGS PER SHARE [Abstract] INCOME (LOSS) BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Common stock, par value (in dollars per share) TOTAL STOCKHOLDERS' EQUITY Balances Balances Stockholders' Equity Attributable to Parent INCOME TAX EXPENSE (BENEFIT) TOTAL INCOME TAX EXPENSE (BENEFIT) Income Tax Expense (Benefit) Statement, Equity Components [Axis] Additional Paid-in Capital [Member] Retained Earnings (Deficit) [Member] Equity Component [Domain] Issuance of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Gross Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period COSTS AND EXPENSES TOTAL COSTS AND EXPENSES Costs and Expenses EARNINGS PER SHARE Earnings Per Share [Text Block] WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME (LOSS) PER COMMON SHARE: Depreciation and amortization COMMITMENTS AND CONTINGENCIES Adjustments to reconcile net loss to net cash provided by (used in) operating activities: ORGANIZATION AND BACKGROUND Nature of Operations [Text Block] Accounts payable Accrued liabilities Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition RECENTLY ISSUED ACCOUNTING STANDARDS Description of New Accounting Pronouncements Not yet Adopted [Text Block] Excess tax benefit from stock-based award activity Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] ORGANIZATION AND BACKGROUND [Abstract] BASIS OF PRESENTATION [Abstract] INCOME TAXES [Abstract] FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract] INVENTORY [Abstract] NOTES PAYABLE AND LONG-TERM DEBT [Abstract] STOCK-BASED COMPENSATION [Abstract] SIGNIFICANT ACCOUNTING POLICIES [Abstract] Amendment Flag Current Fiscal Year End Date Document Period End Date Entity [Text Block] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Prepaid Expenses And Other Current Assets Sum of the current portion of amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event and amounts from income taxes previously overpaid to tax authorities representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also, includes carrying amount of current assets not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year. Prepaid and other current assets Special Charge The aggregate total expenses incurred with the retirement of the Company's former Chief Executive Officer. The special charge consists of (1) severance-related items, (2) non-cash stock-based compensation expense, and (3) legal fees related to the separation agreement. Special charge EX-101.PRE 11 smed-20111231_pre.xml SMED 20111231_PRE.XML XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Dec. 31, 2011
SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES
NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

REVENUE RECOGNITION

The Company recognizes revenue from product sales when goods are shipped or delivered, and title and risk of loss pass to the customer except for those sales via multiple-deliverable arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.

Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served.
 
The Company recognizes revenue in accordance with guidance on revenue recognition of multiple-deliverable revenue arrangements. On July 1, 2010, the Company adopted ASU No. 2009-13 which further clarified guidance on revenue recognition for multiple-deliverable revenue arrangements, changing the way the Company allocates arrangement consideration to the separate units of accounting.  Under this guidance, certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ (formerly the Sharps Disposal by Mail Systems®) and various TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation  and (3) treatment service.

Prior to July 1, 2010, the individual fair value of the transportation and treatment services were determined by the sales price of the service offered by third parties, with the fair value of the compliance and container being the residual value.  Beginning July 1, 2010, under the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting.  The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price.  Because an estimated selling price must be set for each unit, the residual method used previously by the Company to allocate consideration to the compliance and container system is no longer allowed.  The selling price for the transportation revenue and the treatment revenue, which utilizes third party evidence, did not change from the prior method.  The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities.

Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership.  Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company's facility. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company's facility. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container.  Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed.  The current and long-term portions of deferred revenues are determined through regression analysis and historical trends.  Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned.  Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.
 
ACCOUNTS RECEIVABLE

Accounts receivable consist primarily of amounts due to us from our normal business activities.  Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer.  The Company maintains an allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past collection history and specific risks identified among uncollected accounts.  Accounts receivable are charged to the allowance for doubtful accounts when the Company has determined that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.
EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U8C8X.6(Y8E]C-&,T7S0W83A?8C5B-U]A-&$V M,#(X83!A-&0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I7;W)K M#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV M95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!2 M96=I2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,#@Y.#'0^+2TP-BTS,#QS<&%N/CPO2!&:6QE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^06-C96QE2!0=6)L:6,@1FQO870\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M,C`Q,CQS<&%N/CPO'0^43(\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)FYB'0^)FYBF5D.R`Q-2PP.38@ M86YD(#$U+#`U,R!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9RP@7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA&-E<'0@4VAAF5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XR,"PP,#`\7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA&-E<'0@4VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XQ,38\3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\U8C8X.6(Y8E]C-&,T7S0W83A?8C5B-U]A-&$V,#(X83!A M-&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-6(V.#EB.6)?8S1C M-%\T-V$X7V(U8C=?831A-C`R.&$P831D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&-E<'0@4VAA&-E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U8C8X.6(Y8E]C-&,T7S0W83A?8C5B M-U]A-&$V,#(X83!A-&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M-6(V.#EB.6)?8S1C-%\T-V$X7V(U8C=?831A-C`R.&$P831D+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@ M<&QA;G0@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S&-E"`H8F5N969I="D@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B M;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U8C8X.6(Y8E]C M-&,T7S0W83A?8C5B-U]A-&$V,#(X83!A-&0-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-6(V.#EB.6)?8S1C-%\T-V$X7V(U8C=?831A-C`R.&$P M831D+U=O'0O:'1M;#L@8VAA'0^/&1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!4:6UE6QE/3-$)V1I6QE/3-$)V1I2!O=VYE9"!S=6)S:61I M87)I97,L(%-H87)P&%S("AD8F$@ M4VAA'1087)T7S5B-C@Y8CEB7V,T M8S1?-#=A.%]B-6(W7V$T838P,CAA,&$T9`T*0V]N=&5N="U,;V-A=&EO;CH@ M9FEL93HO+R]#.B\U8C8X.6(Y8E]C-&,T7S0W83A?8C5B-U]A-&$V,#(X83!A M-&0O5V]R:W-H965T'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!4:6UE2!F;W(@=&AE('EE87(@96YD960@2G5N92`S,"P@,C`Q,2!A;F0@ M'!E8W1E9"!F;W(@ M=&AE(&5N=&ER92!F:7-C86P@>65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<^3D]412`S("T@4TE'3DE&24-! M3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE M/3-$)V1I3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT M+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<^4D5614Y512!214-/1TY)5$E/ M3CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!4:6UE2!R M96-O9VYI>F5S(')E=F5N=64@9G)O;2!P&-E<'0@9F]R('1H M;W-E('-A;&5S('9I82!M=6QT:7!L92UD96QI=F5R86)L92!A6QE M/3-$)V1I6QE/3-$ M)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^4')O9'5C="!D:7-C;W5N=',@9W)A;G1E M9"!A2!C;VUP971I=&]R3H@8FQO8VL[('1E M>'0M:6YD96YT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V1I M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!4:6UE2!R96-O9VYI>F5S M(')E=F5N=64@:6X@86-C;W)D86YC92!W:71H(&=U:61A;F-E(&]N(')E=F5N M=64@F5D(&]V97(@ M;75L=&EP;&4@9&5L:79E6QE/3-$ M)V1I2!-86EL M(%-Y2!%;G9I'0M=&]P.R<^)B,Q-S0[/"]F;VYT/B!0=6UP(&%N9"!!3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@ M+SX\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M2`Q+"`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`@("`\=&%B M;&4@8VQA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE'1087)T7S5B-C@Y8CEB7V,T8S1?-#=A.%]B M-6(W7V$T838P,CAA,&$T9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]# M.B\U8C8X.6(Y8E]C-&,T7S0W83A?8C5B-U]A-&$V,#(X83!A-&0O5V]R:W-H M965T'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!4:6UE2=S(&5F M9F5C=&EV92!T87@@"!M;VYT:',@96YD960@1&5C M96UB97(@,S$L(#(P,3$@=V%S(#,U+C(E(&-O;7!A65A"!R871E(&9O'!E8W1E9"!I;7!A8W0@;V8@&5S(&%S(&$@ M3H@8FQO8VL[('1E M>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[('1E>'0M M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF M>2!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[ M)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M&5D M(')A=&4@9F]R(&$@,S`L(#8P+"!O2!D M871E(&]F('1H92!#2!P87ES M(&$@9F5E(&]F(#`N,B4@<&5R(&%N;G5M(&]N('1H92!U;G5S960@86UO=6YT M(&]F('1H92!L:6YE(&]F(&-R961I="X@5&AE($-O;7!A;GD@97-T:6UA=&5S M('1H870@=&AE(&EN=&5R97-T(')A=&4@87!P;&EC86)L92!T;R!T:&4@8F]R M3H@8FQO8VL[('1E>'0M M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF M>2!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M&-E960@82!R871I M;R!O9B!L:6%B:6QI=&EE2!T97)M:6YA=&4@ M86YD('1H92!#;VUP86YY(&UA>2!B92!R97%U:7)E9"!T;R!M86ME(&EM;65D M:6%T92!R97!A>6UE;G0@;V8@86QL(&EN9&5B=&5D;F5S'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UEF5D(&%S(&%N(&5X<&5N2!T:&4@=F5S=&EN9R!P97)I;V0@;V8@=&AE(&5Q=6ET>2!G M'!E M;G-E(&EN('1H92!#;VUP86YY)W,@8V]N9&5N3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!4:6UE&5S('!A>6%B M;&4@&-E960@ M=&AE(')E8V]G;FEZ960@=&%X(&)E;F5F:70@87-S;V-I871E9"!W:71H(&-O M;7!E;G-A=&EO;B!E>'!E;G-E("AE>&-E"!B96YE9FET3H@8FQO8VL[ M('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$ M:G5S=&EF>2!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U8C8X.6(Y8E]C-&,T7S0W M83A?8C5B-U]A-&$V,#(X83!A-&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO-6(V.#EB.6)?8S1C-%\T-V$X7V(U8C=?831A-C`R.&$P831D+U=O M'0O:'1M M;#L@8VAA'0^/&1I=CX\9&EV(&%L:6=N/3-$;&5F="!S M='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I M6QE/3-$)V1I2!T:&4@=V5I9VAT960@879E2!T:&4@=V5I9VAT960@879E6QE/3-$)V1I M6QE/3-$)V1I3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\ M9&EV('-T>6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)W!A9&1I;FF4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$ M)V)O"!S;VQI9#LG/CQD:78@86QI9VX] M,T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@ M8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R<^5&AR964M36]N=&AS($5N9&5D/"]F;VYT/CPO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R!T97AT+6%L:6=N.B!L M969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7=E M:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W!A9&1I;FF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT M97(@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@ M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R<^4VEX+4UO;G1H#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF M;VYT('-T>6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7=E M:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X] M,T0V('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(R)2!S='EL93TS1"=B;W)D M97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)V1I6QE/3-$)V1I#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT M('-T>6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@ M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0V('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#(R)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`R<'@@6QE/3-$ M)V1I6QE/3-$)V1I M#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I M6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT+7=E:6=H M=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0R M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UAF4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT M+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N M/3-$#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^ M,C`Q,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I M6QE/3-$)W!A9&1I;FF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^/&1I=B!S M='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)V1I6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT M.B!B;VQD.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI M9VXZ(&-E;G1E3H@8FQO8VL[(&UA M'0M:6YD96YT.B`P<'0[(&UAF4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@ M:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/"]T3H@:6YL:6YE.R!F M;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O M;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(R)3X\9&EV(&%L M:6=N/3-$8V5N=&5R('-T>6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`P<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^*#@P-SPO9F]N=#X\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^*3PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS M1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@8FQO8VL[(&UA M'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`[/"]F;VYT/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^+3PO9F]N=#X\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@#L@=&5X="UA;&EG M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M'0M86QI9VXZ M(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)W!A9&1I;F2!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M#LG/CQF;VYT('-T M>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG M/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@ M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$#LG M/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#L@ M=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&%L:6=N/3-$#LG/CQF;VYT('-T>6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T M>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=&5X M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T M>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/"]T3H@8FQO8VL[(&UA'0M M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)#PO9F]N=#X\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#LG/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^*#`N,#(\ M+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^*3PO9F]N=#X\+W1D/CPO='(^/'1R(&)G M8V]L;W(],T0C8V-E969F/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U M,B4^/&1I=B!A;&EG;CTS1&IU3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)#PO9F]N=#X\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H M=#LG/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,"XP,#PO M9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^*#`N,#4\+V9O;G0^ M/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`[/"]F;VYT/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`[/"]F M;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[)B,Q-C`[)B,Q-C`[969F M96-T('=O=6QD(&)E(&%N=&DM9&EL=71I=F4\+V9O;G0^/"]D:78^/"]T9#X\ M=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^-3,X/"]F;VYT/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[ M(&UA3H@ M:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F M;VYT+69A;6EL>3H@5&EM97,@3F5W(%)O;6%N.R<^3D]412`Y("T@15%52519 M(%1204Y304-424].4SPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)V1I3H@8FQO8VL[(&UA M'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE2=S(&-O;6UO;B!S=&]C:R!W97)E(&5X M97)C:7-E9"!A3H@8FQO8VL[('1E>'0M:6YD96YT M.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$8V5N=&5R/CQT86)L M92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$.3`E M('-T>6QE/3-$)V9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`[(#PO9F]N=#X\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M(&-O;'-P86X],T0V('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(R)2!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)V1I6QE/3-$)V1I#L@=&5X="UA;&EG M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P M86X],T0V('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(R)2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)V1I6QE/3-$)V1I"U-;VYT:',@16YD960\+V9O;G0^/"]D:78^/"]T9#X\=&0@ M;F]W6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT M.B!B;VQD.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)W!A9&1I;FF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V)O M"!S;VQI9#LG/CQD:78@86QI9VX],T1C M96YT97(@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L M9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R<^1&5C96UB97(@,S$L/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,G!X.R!T97AT+6%L:6=N.B!L969T.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L M9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)W!A9&1I;FF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^1&5C96UB M97(@,S$L/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,G!X.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/"]T#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@ M:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^,C`Q,3PO9F]N=#X\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@#L@=&5X="UA M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE M/3-$)W!A9&1I;FF4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^/&1I=B!S='EL93TS1"=D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[('1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V1I6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@ M8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0R('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UAF4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7=E M:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$ M#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^,C`Q M,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,24@#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E M:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R<^*%5N875D:71E9"D\+V9O;G0^/"]D:78^/"]T9#X\ M=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L M9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O M;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P86X],T0V('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#(R)3X\9&EV(&%L:6=N/3-$8V5N=&5R('-T M>6QE/3-$)V1I6QE M/3-$)V1I3H@:6YL:6YE.R!F M;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M/"]F;VYT/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE2!S='EL93TS1"=D:7-P;&%Y.B!B M;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R M9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^+3PO9F]N=#X\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@3H@=&EM97,@;F5W(')O M;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT M/CPO=&0^/'1D(&%L:6=N/3-$3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,BPP M,#`\+V9O;G0^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[(&UA'0M M:6YD96YT.B`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`R.&$P831D+U=O'0O:'1M;#L@8VAA'0^/&1I=CX\9&EV(&%L:6=N M/3-$;&5F="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B M;VQD.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[('1E>'0M:6YD96YT.B`P M<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS M1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E M;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M2!A3H@8FQO8VL[ M(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&-O;'-P M86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)3X\9&EV(&%L:6=N M/3-$8V5N=&5R('-T>6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^2G5N92`S M,"P\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I M9VAT.B!B;VQD.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)W!A9&1I;F3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F M;VYT/CPO=&0^/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$V)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@'0M86QI9VXZ(&-E;G1E3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[ M(&UAF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[/"]F;VYT/CPO=&0^/'1D(&%L:6=N/3-$#LG M/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE M.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^,C`Q,3PO9F]N=#X\+V1I=CX\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@#L@=&5X="UA;&EG;CH@ M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^*%5N M875D:71E9"D\+V9O;G0^/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D(&YO M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)#PO M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q-24@3H@=&EM97,@;F5W(')O M;6%N.R<^)B,Q-C`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`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`@("`\=&%B;&4@ M8VQA3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE3H@5&EM97,@3F5W(%)O;6%N.R<^5&AE($-O;7!A;GD@8V]N M'1087)T7S5B M-C@Y8CEB7V,T8S1?-#=A.%]B-6(W7V$T838P,CAA,&$T9`T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B\U8C8X.6(Y8E]C-&,T7S0W83A?8C5B-U]A M-&$V,#(X83!A-&0O5V]R:W-H965T&UL/@T*+2TM+2TM/5].97AT4&%R=%\U8C8X.6(Y8E]C-&,T7S0W83A?8C5B 2-U]A-&$V,#(X83!A-&0M+0T* ` end XML 15 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
BASIS OF PRESENTATION
6 Months Ended
Dec. 31, 2011
BASIS OF PRESENTATION [Abstract]  
BASIS OF PRESENTATION
NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under accounting principles generally accepted in the United States of America for complete financial statements.  In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of December 31, 2011, the results of its operations and cash flows for the three and six months ended December 31, 2011 and 2010 and stockholders' equity for the year ended June 30, 2011 and six months ended December 31, 2011. The results of operations for the three and six months ended December 31, 2011 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2012.  These unaudited condensed consolidated financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended June 30, 2011.
XML 16 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2011
Jun. 30, 2011
CURRENT ASSETS    
Cash and cash equivalents $ 18,343 $ 18,280
Accounts receivable, net of allowance for doubtful accounts of $24 and $26, respectively 2,600 3,065
Inventory 2,483 1,770
Prepaid and other current assets 917 857
Deferred income taxes 233 203
TOTAL CURRENT ASSETS 24,576 24,175
PROPERTY, PLANT AND EQUIPMENT, net 4,993 5,350
DEFERRED INCOME TAXES, non-current 890 748
INTANGIBLE ASSETS, net of accumulated amortization of $242 and $227, respectively 376 325
TOTAL ASSETS 30,835 30,598
CURRENT LIABILITIES    
Accounts payable 1,193 965
Accrued liabilities 1,331 1,260
Deferred revenue 1,773 1,724
TOTAL CURRENT LIABILITIES 4,297 3,949
LONG-TERM DEFERRED REVENUE 329 401
OTHER LONG TERM LIABILITIES 240 383
TOTAL LIABILITIES 4,866 4,733
COMMITMENTS AND CONTINGENCIES      
STOCKHOLDERS' EQUITY    
Common stock, $0.01 par value per share; 20,000 shares authorized; 15,096 and 15,053 shares issued and outstanding, respectively 151 151
Additional paid-in capital 22,003 21,602
Retained earnings 3,815 4,112
TOTAL STOCKHOLDERS' EQUITY 25,969 25,865
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 30,835 $ 30,598
ZIP 17 0000898770-12-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000898770-12-000004-xbrl.zip M4$L#!!0````(`+IE04#EE98WIC<``,#2`@`1`!P`BE/=7@+``$$)0X```0Y`0``[#UK<]NZL=_O3/\#KGO2 MVC.235)O^R0=Q78R[DUL7]OI[9G.G0Y$0A8:BF0)TH_SZ[L+D!1%41*IEZ5$ M9W+&%`DL=A?[`K``?OW+R]`F3\P7W'7>'^C'V@%ACNE:W'E\?Q"**A4FYP=_ M^?"'__KUI>?;!(H[XA0?^?N#01!XIR>:+*UW.IT3^34I*GA>00"KG_S]ZY=[<\"&M)K% M!YNW1A73V#1/U,>X*!=NW=!;LXA5)9(*SA,3P3ALPU?1J M38\K`:K*%Z$-.%8OQ_$;@0TYQ)QSFTV`%_DGPZK$3*,%\;B85 M7*=`'=>I9NJ9;N@$_FL^;M'''/S,T/>GU($O()-YE1S*39%?2W[*J2*XF5\! M/N05#[PI:.&7G`KLQ1SD5\`O>2T,F954$`/J>X([YK'I#F5AW4B*%E$X4%1" M?D4-.152]N]8GTB-.<4.>W\@^-"S41'DNX'/^O`.4*C&C1V_".N`G"A`4M&A M2YV`O02$`Z)F@I0LD91A3L"#U^A=\I9;^+[/F4\D.FR,AI@SYU?_<_!!@__: MG7:KI?UZDJT<-W62TU;4D@1\`Y"&0 M=OGO$*@[=X>>Z\!/T7WAXI_P<^@Z]X%K?O_*ACWFOP'[1UQECXAH\CKZ8`$: M+Y[-31XH'(G%H9P:<43Q[>E,,@\^Q,4FZ/WU)+>)$6HG>;C]4`I83F*ZEL4# M8#VU;RFWKIQSZO&`VC^%],RD?2]))27IC@64.\RZI+[#G4?Q4XA0/M%[V8$P M`,9`>V^U'=XJ-W?SQNYF>T1A[R\V[B\VV/D[,>[;%#^2,&KO M%+?'*2X[Z,],F*YG#J6(Q.Q]ZC8-X799DO8N^6V'<%LM.SOAT;>8G7OGOT7. M?T,+GWOOO?W>>WM$8>]^WW)$O-8$B/W2W7::_O7E`.W7WG;,]+^I*.Q-_]N: M_K5U_NXDP8Q-AJZ-'_!O1X:2*7X8,D5W):%!Z'#%C&^:EI6+(:,B]-F'*(/\ M]-O]10PI_I2&CJ"F@38RH"W^!"S)DH@UKC%=FP:NG]7TPOBDF9`/,=7++D*#@2S`B*`I("D8:P4)]6C;HQ1F3Y=K>2]`+] M6S6,UJI('X6MQ(.XMC=-7IL4M(K607C57 M0&H<_)-;"/3NT<-6R$BJ.9C0?S$-7UHHB>4S&0L8E\P#'M$[5Q M.%LA-("7OO\*EM8^"=5L1O$M62EA2R-WJ[5QSU!H;;>DJH" M1D5O&VUMIZC2"E&E-=N[1541"6RUZZTEJ+IR3!\&48Q`')(,!3SZBFY"4@LO M_1""2)O3'K:VAR"B^"PI9PHU_?U^CR+6HH5 M:AA-!(ZC*T3-7Q(:!@.0G=_!H1P"7]3;HXFP830"ER&QZ(ZJ%0A7:VG*-!CY M9X*ZZ=`WCOQD_+8NY+D084G$KU25!3BN-[1.T^CH,_!6P#>&\WQ&`\Z-6DUO MEL;Y7N&LBE3(31C@$@T>6S07VU39-;$YU<*F\%X)JQ?#.UV"_$,MWO[_4M0L MMI=P-O7U=D=O->HKISXUQ7H;3;%&4YJ;X\7LO)*9?)EEY19C2+S(3Y+I'G#+ M?5S7/]H<1Z:D5VR8%4M3N6F$5Z_*BR5!OXTA6[?*'TXS%9*3R![F:F'=,V)H%1@S M38[:SHC>J(!8RN$W/C9JF9$&?G!'3<].!DDAO<1*2D.?-K[+3,/O'/5%UB:* M4R]D,H_/GI@33LZ)X?>;_IWZ6FYA=G(>))N3,P9\12C-7(.=G):KM=>/4LG9 MSDZ[LWXNE9K`:K:U9A&4\I,6HM=7CND.V0-]B6:W/C('K&E>0D89F1I//)G= MU(H1+2=IU4Y;?SM6J:9FVJ3*+),Y5#@S.HD=";?[HO#_X5R@"WG\]``?]:K/W!Q87GDU?3TD/(9^1(?4? MN5.U63\X)9H7G!%L":)73!:/WD1E?/XXB%X=Q"WU`;,)T-RQ(>8Z(_BQ^LQ4 MM9YK6]$K`6[_E.@2MGS1IT-N0\4'/@2O?\V>R9T[I(YJYOKFX9(T297@PSVY M[?[6_?CEDG2O+\B7F^O/U8?+NZ_DXO+C`^)S@O!BY$XR+)G"@@F"$^IZ/CF9 M!FQ;^%N.F0\#1C!$IL[KGP4Y]QD,&$CWT6P0[ZT)CI^I[KPZB#>"$\"2:.@3'8S@4SU?Z?FEXA MJ)V*S(CA9$`MXKCI4!:TPO?=9QR9`-_`]$!Y-Q38(HP?)RD8BX)E9GC]N)/P M>E2./E%NXY+T\5XIYBO%%;3;"YCE,"'`\%O0@;+;LMK!!1',!!FS2.^5B+`G MM[QP:MNOF,V/_`_&](O*E<=C\C'I91!N&!MQ,.<@J0$F*C$NUUM1QBGIVZ$9 MA*!?(!I*PN`3Q4L&"/MW"+('HOGEZN/-'?'L$.!'7,*6C89&>E0`CI[+Y?X! M7^D(M#&.E>NAJ%>P.?X"M,B&E!+7M`IIPO_PHZ,1"Y11[>`!NH,8D*H.'P,& MP`IB`QH""I"6?`B\7?L)GVR7.J(REM2#SZ$CEZ9C7E7`.`&/P3A8H5JHCK.! M`)F_AM`%,'9$I3.4T@TI6`.P-!+1I&LR77I,4@81`2(5?2;+:\?&NQ3_H16$ M$#JA0`2'F/L1@QTW+GF:&\-BKK(++,Q`J,<_`/M][D/K.9/2@@= M]JA^F"Z,YB@J'O9S!24$9-N5RAT,E(7W08DYQ(!IIP!]/@3("!TUB#M\"-)F MP]A0&91X(PGN&@(G"/Y9;@S2$ZLOL7#!D+R@+P48/OIG+)5*C9.BE0M*!V<- M'^%/02\&.HU[).`7P,=T?!DTH/WK^8[F,;0E[TH[92,4`"BW%JG1"#-G"A^B3K: M2F#PX1!8@#4P5>5U&&&.7.-I[Q-9@`B=*=R#:(?C]%C6\,U6[_AY-&J9,MQ( M#5U4/@U(S@LY[*EAX)$*ML1$4EY<>CT3%9D7?[N\ M_G8Y!\EKUS&78&'-Z,Q"NU0J`RQ-L6#-1RMN^FP6!B_^PMRJ4,'M$&+=>;L9HV+KW,D:-;%.;%>YGW4#Z*YR5^LF MN+O"O:U9=.5*?Q7O6[7D2!>B0:5%4^+5>(,LL\[3I9V MM4$JRG5":0+4P(=`I%YTI3(9*JUXN1(G`7=]K;)!JN3J^OSFZR5YZ/[]\GX_ MZ5IV79+U^RJ]2\X6).L3.#,F^`L9`K@!E`)S2"-IN%J MM6/M77$PFHR]H%)[5*D/LDYM@JN<4:V_A@Z3BR9J=IT.O;,_0IQ^)N?MEJ." M"S(`QN-A@J&:,48[;J(GY$"5*>J?8H(<3HA""6B1F51@M33Z M.%T8U=O@HL#D%.0L.S(R3]O/5W+5__[^\N%^=(96ZE0EFHYVU>%91G1Z MEM&:G3.8/?'HF@67+Z8=XD+59]>UY,K30B/F5G93_/R&MIWL(ODQ1G9;>!FR MHXV\.>A&'Z#Z8E-I]8E=Q".(R[9?:)ZGE=W4F]/^E^D'&LP\K:%(.E6[V9R6 MM[1T^T6F95J9R,?0?@M9DO5/G%U%5KUQK3$,QM9NU8 M%SJKK]%I+X8U2K(\/N56)?/(Q(;#;T).'1^13VI!SWDD730AN3*!L[H`(0;P M\15K7SE)U5'-9>=5QGNF>+M;0FVY&+Z3T=35DXO&1P0+D9M475GG5HU&O0B] M.2UO";TEDV]K-6/-]-YX>.+L0O0F55>GO)U"Y.8TO"7DENS>=J.0M9I'+T3$ M>42HJ!G']S6(Y`+XE(R?3^=F;B:)6HE#5%G?6A4C9%OZE-F,59N!3: M@ED4PQ7L2YXU-36'E`7V4ZZ2L!);*9<@M MEL1E!1I2[@KX'=*0E+7L MD61%CE;-;WF+:"[I@@U#7Y[J:]=QD_@T6FTYC++,)JA+%U9EX^/9E@OVQI-W MIK:R;J3+!89Z8SNP+G]XWQ8@74[4LX.!N5C?3*`LUT"S^-Z,0UG!L*4V'A3G M-+`.'$N.:'0CXR`E`R8V9>"OOWEW2__]]O5[=?+ZP>YQI5#"71W\'IK4R<`YXN.U\.0;=&5H'JG,]$9 M4UO8&.(%QCL-N3Y1&G&UXT1N+^F::@_2Q!TU$[A'E1[#FI+FK=Z>UEJ MD\$KBT:/66*RH\O454O1*'>Q=W\YZ<2ZR-JSKQL(XJST%]Q,ICC`X M$W'.?ZZK*!-U-HT,AAGP2Z-3+L"L-W5]K>B4-`YZ)[/FL7+VE%M`;=?KA=!) MDC"*YSY&%?:YCQ.YC[I&5!9;+PK$*)4\\- M`G>8-%-KO%M%9^?C,,H5G>R]P)J/G%X&MS+*/0?=.=B:+G:8@YLNIF+>'*$^ M*1`[80!S>93.X9V]$W^,8X[[[%/O_8'Z.YUK(Y&7A,M2IP3YL5$J"TO"7FYW M1&[C)/:?769/4C[!)[U'$`G7?W_P1]-DK-\_F"_:Z"]B2B(O5E5%3HGAO:PD M%)$=L`A[A=DKS%YAEG>ASP,>L((.].U]Y#YPW9'` M]?";0T,+1,LZ^MECUQ6)[7;(Z)OAN5G1V-HQS$Y-I>8RZXX^XP&PS.?4%B5L M0]%H[\TE=9LD\Y<%<6WD(RN9OSYL]8K1R@G>?C`[L)?EGT&66QWMAY?D%0PI M"HW-=]?9?>(.%P-FD4?7M=;A[=YX3G-I\U%F[F(;1+Z8G2E#U?I]JFZLW!*M M?!+DQY@BW*O1CZI&G?;JW?E.*-%:5][J/X:7?W`#:F_0N==WV2H!\L1RPY[- M-BGL*Q@\E*)FS>;(J-3;M;4;I/HV&J2]_NSU9P51<:NU?H>^E?J3R9U5O*UWE-C[46WI]*;K`BO`^ M-RD8CJYIXCUWN./W%H9#)IZ,-6MK1*KNJ&I<K\ZN?]=CHI=D;[2XB=Y?G-\#?AZN;ZY^3 MDPL?P$U\9KJ@Q[]#J>CR([7S/+IXA`C<246>!\Q14\YR=XH8<,]C%EX=:C$; M[(K/++65,^"!K6[*\[GX+B\FQ!,!/#JZ[T[=`,A\>8FA%T3G9+M@"U5;3YR2 M86@'W+-9-0(O-XQ0WZ?.HSR^1QRKDP&%O,<7(9C,E]9)0R5QB?%0)%%EPM0UQ+C]!DA2%Z_(*Q`5:ES=3BCH,+Y14/[VF3J> M615":,A5"$ZM_26\\0D?+\ZZ!E>J2B^A>2+R,4>Z62LN"NI32 MXL#TH()7+,HGV>'J2DZ@Y3L+0`C]`)R31^4)1-#%S^`L\6_T'3R5.N5*()3H MR&J0(V[B&9$#8(@ZAU)>N`&"[N*EC7=*WB2J\?6OU@AI]'X^Q7M^;85\A0S` M&[L`-+K*VN=XS66%!#[#F,*A]BM>I2LOO?7=?ZE3X"&>Q M_[1ZL9NYQZNT!&_8G.%=JR:JX^@"T\>0JU^NDQ2+:L9'J^=:H+CLN"6ZB:_F M5)<)C-^@2BW7PQ[LWG\CU^XQE-`Z5;T678$>7S=JVM"/?8[K>G-00^M4&+<* MBJWSB&*,.#WC=:9IW&SHJDAZDTHH9();\L05U#IEM`4#[<'[!S`<%=&Y]%', ME[H+8?3T+;K,&$0Y)JF2&.G(-B._QI96 M=CBHVQ,;\29V3*_Q%=F'>#V-)T!A\<):>'__*@(VC':PUMO&&3D$YH)#L!4R MJGP9@6UI[\X(P`Y0N>,ANM2#P/5F#JG5A2U@$8`17RFW(^36U'JK/MZZNO8^ M-B4/]#OKHJA<.D_<=QT4"L#L3OK1!+$4V_SDND\7K6F\)]C0SI"4'C6_B^2= M?B;;6B=OL]21VW#HJ=O5\#2.F)"/[@N3US1/0UY64X73^"MFP:A'*8J0ES2$ MGE(4GZ54A=FQ%H+.)GHS9!3G.BJI+;ZGY%`_BB(+.[F_W!S=NBQ;=.4-RB#B M0G9!A1P:1U%T`\Z#.B!!H%VHM'GZB"`.:T?H9JBZ\AA=!;BV?8A2*$3A&*6Z M.88>XXTG;J&#[U/NXZQ>F/3A>+^H"#G;`1B'^&BOU$W3(VNHPDD9?\3PHBKC M=I/[EHIM4)ZE?Y,7V$P@,U6@>BSV$#X3BA19,=>P?V3`=#RD(\.+T>WU,AS& MJW"$FHR(2!@RB/*M_[1W[;V-XTC^_P/N._#Z!N@T8*0&.X\SZIN-D M;??,S2T.`T6B$^W*DD>/3GR?_JI(/2W9EOR4'`([V+1%D<7BKXI51:K*,JSG M>8V5]`ZMI60[V#%BO.)AIL:W.U_Y_`9T`(=:B\/:$-H-OEB7W.]A/*`RD M$5ZB?8T?@L2ZZ!L%6ZD6;)BP)'K257DK.=>$C(#/94U/&P;@L[+FH_?PK9!L`:;82,,"UP]H`Q;,&L M5S1#EW`^.9.@4-*"L(0&C5]V/1(<_TG--Z(\5S>8Q1>)`E:7ARDPHT/3,?3N MI90&_`E6P?'%,$Y_/GV==&0"[Q1;AGI@%B2[C[R/6*=, MLG&)C)I?"PI?OJ,:"T@:RBLZ-1I8DSAM7#;'M:$+9!CH,6^"<,]YW0EU&>$U/F5J0R"^N2B"TF3RPK MB+X$9`/;".([MW(=P"X'!]@<'#GF0HQ@6;SXD%;Q3'\9#&((AC MO<)H&/7)%I1LP4T2QT)(B4&#R$P>X8DP&#QX`?`]41K3V#"_F$K[".:5HB(" MY^=DG$^#3<%>70AKH:)44+_#CF1RY0T[&)A]NAH*K!WP.G/H1;65M6CXL@8B M:?.0$U(`]`$!3F`VP%"X#A,^W9F[8$N`QX3BS!@RHS9S9$)E$TXU<_5&.M,7 M:07LVZ\9"CBP;)D'AAM_P*Q0E?EKP7POGMT&-`&HJ3RHKJTVFV)LU`+C'7=Z M(VXA<=)"3BS5[T'A<1P"-Z\Z&AX$AV91%J!46Z@-SWN.62A@]5O>\PL\?X9- MUU^P6!0G%N]A,1XGDY@['@F86N@:K.H22(KUJ"FND@PXH%PDJ$-'.?*\J8V? M`J+&1B/)K_D6EP,'+\-AQ&G.=LTGZLOI$B9V6&@%L&>@51=P+I?]FT!13"(6 ML8.8.6A$JRP;R-;G(_Y)TP@/2'K]WSHW7WIB*\[!-M6/0_.MA6>K\IU],/F` M$GB7R<^4MV-5.RVPL;EU:7DVR(X]Q7B.YP`5CH/.AE_T9ZD8+0[YI!BH'-,* MQT*I3"WDKKF`6MW\RT-)#?=N/F%4O3,%F('S3IBUJ7!WY(\&V_Y:4QLV8::1 M'+[O@B?!M@BTB_!BCSOQC,"[8^=&:'SF$NXP&.? M>C:?X!WX-]>Q@8^'R:"WP`W;=<##\Q1\D]RKCX@:'"[X9 ML6[2X7*LTOG<"0R'8?4]?84>H];4/L,0T?KR(>+&52P\EG"P8KR"W<14?2LK M3I(2-@9C#I=/)5_IQ<]97 MC\9F/`:72!&/(COS;-`M>+0.&H8Z@5D6^2DJ+Y'$7V1Q2!IFC(\'J`^[?OL` MPS8Y*-N'R4'9:IQ*2I0CYI:02D!G];_$%3@0.!`X$#@0.!`XV.G7FVCC'/GC MZ,T-H!T1?H2$<9=+P=9HY/X^.NO+VLHGEANCJU6_YRY6#UVLU:&(LGVC78:D M/,)W71A`VBQ_ MEB@,\%XU@A`8(3!+!"8C18X0&"$P0F#$#B,$1@B,V&'*&Z<\OA=6T5I-JV,K MIQ@S$;6:!&P%;*L,VYT$]4YCQQ!7EBI^94G@0.!`X$#@0.!`X&!//G$EOCG+ M9-6#_ZU8^-57`#*(SCO,4YBJDY M18+M0A?D(GK#XFK"3A.>A@"N`*ZPQ=X3C&7A4P@=V8[!H3+!EW*IDWJ^5B8ZE6AWS7;LOA,0DK MA!)+[\UK;&/)()UE\N?/6&EBT_'K][SAWU%Y:M<"P)KU;_`29O=^56S-\2M" MZ4Y4.H&7EUBLJZH0_ND!ONE[8'X%;""L<7Y!YE2QBZ?QSYM6/\SDWWM3L9R& MJ[P!E2:=8)4]5G2#,:#.ZSFPN04E-^:+N?QY%V/E[89W<`>O8T%2>H,O=V,L MO---Q<1DX)VP>L?:_/ZL!A][^E62X)\:5;'N@?/3AWKSP\]R0Y*D:/Y;D5)> MGD@A3Z0"B_>/K*ZP%\6B3F=U_&_2#+P$/E]##QWV2+X#QXKN." M]N'E"1?Y)BT7AF:<<`EDH74A741$%QS[D-.2PFEEX#DUK8MV0ZK$M%:JKO1J M25=R)::U4OMDK):\`Q"":M+5#2:5ZI%WM*5<25=7:Z>4/?*A)K0'B3KNA/8@ M2T=>H=U+T9H)\5TK>W_<:(=N2M?-K(UQPQ%S;,5-J=6^7C7B`YKW6-_7FM+% MVKJ9%DG*[1!VKQ*T+-LD-U2N%*\TT9QZP@D%K/;+X_! MQ$)6=..Z((GCO_6&Y,O#X!LX#RU2W M,IRE!*G+N]\WL7DD^KI9E-C;WEUO..S=DOZ@^W#?(^/.?_=&->9[J]D^P*U? M90]\'JXO!M3=DLG7[2235P]Q0-IS\/SJXGHCVJ-2?M:$Q/U$,O1#(%W+05>, M;42^7_RHS'D5VE7E_Z*N'R;QCOU^6;>1BQITN9.B@$>/:^VF+N`5X0')ZX8L M_T!&XX?NK_6;S@B0!CA[[`U&':P3N#)\)"*'K,]1+*B3B/>I@$)6Q9PJB-2P MD/*SK0`%&@"UME"M53%4CPO&1-%M#%][875N%B^JL3!CLF"YP@JS!L%%%AQD MI5>G,\.:4_H1&__EZ8[NAM6X@U#AV3,UP2(TC#E[!7"!<6S*SB>?@G8C3GZC58C\RZNCD5_#4#;&GZ%3`RO)YEOA`L4Q^?HVKR[C M#&H66M_FLN8'6U]P&^/D7Q1:WXO+1EG65ZCY]6I^2#5/Y1_G(_>5-XI%M^>L M;"DPTS.8ZF1A?@S\:U%S5OZ9ON&G-D$5Z$!WQXX(0(\[EJJS96-%NC//CLYH M^FSA$Z]9;4`'?A5LATR"2#QL*LX+F6#56`XHMEL`W&R*=6BQC+2FZ3@&(&ZF MZ!RPRDP'@4]4D/[HD(RQ$\#%?\>&8[R("(DJKF^N+^28R#`A:E]>A+\(4!<& M=1^5D_E/S^2%P\/B\#9U=9LK#E;TF,X4KCJ(\@R;>*!1;NUS(WTN`5CQD'XW54SKA>7[SJ!3(1'IG$LXE`C MK!,//799.??`RL(2YXP$!.42!9D?H=(!<98^K]W2#PI=M3LT-W]CYF;4Y6H7 M#%]A;\1>V,[!*LRG0_E*H(;BSM)=IS\DOW6^?.V1ASMRUQ]T!MU^YPNXZ*/Q M\.M];S`6Y=5SL#:VMS"C1<=+!TSHDLX/N"?!+@*RK)M@#'D,QC5?X,-=#A4& M^P-=%GB?-T)Y]S"@`!J'PL^P8<=^#+9PMJ.HJNV!C!M1.`E#+:Y_!6,*(F7K MS%O2=-!S+)["-_P7"A2KBFTSI<)(=]#=PTL8=5`<1//87LL;.B^6[=:ALRDQ M%1<$I^@UC96RMW@-80S;M7]RSZF-1UOB2J-&'K@"A"E$!_B;WTP(>SO^;8T, M4BK%ID-=X%C%IS/8^IC1^"DR'V&CU?Q@8.#=I,/KO&WP=M\,PH=#_L*6F*@W MF@N!]C7C'7Y"!5=O\8`H[WSXP0(Y^V(YX!,P#'>!$MWT$*H/D7'S1,&\H81? M\"+W%*PMC40'%*#T_*[&Z.742.\-_$_+!D6KV'/2!X,)?L2`+_1N6X:!W0?G M&1G<@IZ0)$1=1$]$S@VCAK=C`][KIF4#94&7'5-+]L()YW3'R-[R7.XBA:-# M$2Y6<-D*%CNWK,OR]>+1I5C$HR]B07U^T5H\.15K>/0U++:%P9[0Z"&W'>-#[\+)U+L9M&.08YYG329\.[FT[\JOG'0(`ZKFOK3Q[[\@'])>@E MXX@[?4M]LWL/K?9ETM9*=WPHR\Z->2D(,!6TD"+'^S2I*0@Q\;24+S6LZ]E4YH)]_M7"K M>1W)7$'W'0>/V6X]&\,=C^RV88T?/]?(,/J&FK?N\(N/O]C@]A=0]'P0/@8? M@@T0=<]:L'5U8=9:'I4?3F\48O(W>+`^SCZ M)"B[U@O*KFVO+=DSO]^PV](:F9G4[H*/.U:1^^#J-NIQX MIU+<&V/WS;-UV,HX^CHT"PZD!DMA,)Z6#CRW*1J8WKZRNA/_=J8Y89QT?4G[NW-\O, MZ(/P\&#L6/(U(>G8MF(^\V_0G^99J;`"KOBV;2VTSEDF"D[&#K3K$0*6B^R^ M;+1R6/LKR#T8NW>M M3/CK.;E9:*8[+$\?:_:$N;*^Z2Q'ETE=/P4__HR)OE(ES$Q6F0*S?JG^U^YL MJR!6K+R,QF-)^/Z,;2?GY':1J'W0H$Q<^#G(5!:0$$M M#`4T,$R.L-3=T133D*M$V8E,7HXQ_7_]GB?3[6$RW=59+[>L[)L%';)-N=_# M@4G(Q7N2BY'^)J2B0%ULUR9/SX`KR_[IPW^J*@5+\,-ZX1';H1#[4HE]/)&\ M$'DA$4(BA$1LM@F^ON@N/8TMT"><`7#3E2S?NL7%O[%\6E)N\4^`EL'.T`3,;#$Z$/A,`(@WP]; MOD"EXWC^V,HIQDS.OIJ*IX'_KWW:JSQ60/0$;`5L*PC;'03U3F._.*Z9=W0Z M#PON$BM@@0.!`X$#@0.!@Q/!P4Y]XDICC:`RY59.NJAS5$@<,I>!NN4!] M46LW,JZD"U"7#1_EYFZY0(V:.N/#)`'JLN&CW-PM%ZA!4\M5/I$XV+7N7%_4 M5=>/Z?$,GM8D2DZ:2&&Z!^]E1]\H'DVW%/D&L0Q"D$OW%)G4GG53L[%[OVCG M7S)6-=>2D)H3E9JZD!DA,Z6=E)"92BR3D)D234K(3(F6Z7"I;ZOK2Z;.Q-86 MDA#>I=!?!]9?[N)508D*,A!B5^ZA/B%$)$"?$J.J'BT*,2H`X(495 M/\ZLA!B)SZ^.+=UE0T39+AN\H]O1`LH"R@+*`LH"RM5@O8"R@'*E6"\^OV)] MIM*XL<+8\7.F-!.7'BT)W2!TPRGH!@%E`64!90%E`>5JL%Y`64"Y4JS?X5%# M=5V/&*M6_G6C.+I:P`O)>Q9Z=!R7";>52@,IG4OBXWB!Y!-`\AE`N55A*(N4 MO`+!YU)#(%@@N,H(SJJ7?!H(%L<A<;_NAL_ZV;?0XG[ M0G5;."5E(UKH#+']G0@_!90%E$^$GP+*`LHGPD\!97$^88& M+@E13%>O!\Y+`:]$W)Q\-RJD)3=/7G<(1+\G1%_(5;[4+A!="NZ6"M&MYK5` MM$#T"2'Z/>CHF,?RV56>#)II=_M___C9<^K/BC+[OJ?8IFX^.X_4'N$1PQBF M=8.^R,___F^$_/@?]?HMG=E4U=G])S#Q-3R$L%W]_]@/]3IO%W07;PQ_&Q3_ MZ)A:)_8.46$&,,R03G[ZH#8D69:N)-FU\"^YT90_$,_4^=.OD@3_U*#'J6(X M/WVH-S_\W+JXEB0IFD&>(0\X&2F$0Z@UO2 M?1B,^X-?>H-NOS=:G$S7FDYU=PINI`/]=8%J6'9JJCH`+K4@F92_.?KWIFX` M]&V/?B"?#T"'=-F4\M,Q4%S/IL2:D(<9M15^E^\?B&C"(/V_B[3P%QXFL>;K ML/FS[]"7T;=_I?RU)\O0UFF:,=,T`]`TPUA&Z8=QC\BD3AZ&OW0&_?_IC/L/ M`[:D-YWNK[\,'[X.;E?Z]IO,RL$B3P_]B1:(4_'FBFPK(@&(`&?`#$P\\_L5KJ'C*&VO@VHKI M*"J'*U-A,!([%0;@HPZ?.02$;&;H\`*%/^W9.6NG0Y/7%\LPYL1Z-6%0QWMR M=$U7;)"]6OK5&NF;ZCGV"B*D..1,>U*6M?H4OD_K8\LRG'.8O=_!&=_`KAL- MZ8=DH_"!_$/4P;UB>A.8GV<#YW@7X;.>^4VW+1/9`YP84?N;KB+M?)P8?=D- MP[GX1#.V^&^,E`EUYT%7*K")JAC',N"WU`1BA">>_DYC3XAEX](MCZ&Q5[H< M)7%6G&>]TC$`&R`,^D17%1,SO[O4]B$600`GE`#(B_*-DB=*34(-?0H@0K1Y M,[YQ^?B#AN>KPW4ILR&M.4,MW`EHF2ESM$,6E6[P_)$_[GJV#:N46([ M9['UW6;G;%Y=GKH(5V+G++;B8N@/+)7/JPK)9,PS%K`I/QSI^F$"W4:_)3J'//Z@;]+A%!!OC MIU4/7U^$\3A9_H$,>]W>8/SE#](?C;[V;DFGVWWXRDXGR&C<&=QVAKEDV?/<._9@I"@@]'5/5L=I&%M>B]J2^*^MWX/3&8KLWO@>G3&)FZ";]/HRO.C!3==%S;\R^%@6:\@R;` MM/K?L4G-IQSX@=?=-(N8EAM>/U2,=)\3RW*A#=!M8[`4Y^\!]^QD+`AZT&"%$@O`G^&KNL/F"X.9R"0#`V2> MC=<7XVT_L6%T8!(,8E(5U)YBS]D\8;:*;B.4(K7I(V0):3/+T>/-NL%%P.Q0 M68U#D3J>P>^)XEU0*[KUC$NJ*LX+F1C6J\-HPA?<%YM2]M#1WPB8V>Z+0ZB) MF5%30[!FZ#?Q]FB/OX":H[;SD5!F083=SJEB^]W\EV=2TI1B7:P?Z9R,DY.) M360SREE8TPT71G-@`N81_?%S MZLWHZP7_AN(=7[D_<.X]`,XML#@^KM^.-\-6T`C;K">A7IB=;H"B2=,3 MMN`-BM*Q\/KB^`%RN"BAJ.,VYF70X;<,&_)VZ\GY@SIQ>K*[622+$0M^CDN? M+7N>)H8]#QZOIZ$#.[:!"A;6G;T:IRC1UR(AC]Z3H:L@P);BILG@3]G#=/!M MG;?3^O!SJX'?@4E2G)Q8GXO$#.DS[-,V7IT?*%.:IB=J@,_7\V7TM\[P<42Z M#_>/7_J=0;<'?PX?X]0D>TRA!U82;"+P0S7Z1GZE&2OE-V$MH,%ZFI`?U^WK MJZL$5Q:Z21$2"_KY=P8<\N"YL,FP#2R#KBCFQIO'6J>(A/\MAD^;\;64P'%M M2>W+1EM.$+UBC+2NC"OO._C1R=*6DO(86WRDG, MWS-)B761)F8\GV5N&_C[^@'1.T@.B>^%HSRBXZ.CTX)1`HJ&A48>P'RP0\78 M<1SJAO-WIE3[WG\K>`G>8:_X;_`7-OJ@H2U?,660>Y2C3"3/#=#6IA,9S2BS M#KL@+\\T0:W_B#_)X*]4(,P4T);HBE/=7@+``$$)0X```0Y`0`` MY5U9;R.Y$7X/D/\@>)\]LF>2;,889^%S8GY MT9(=`Y8@=/3;O_[ZEV\9PC_/Y(\7P.!`M,/L;,70^=&,\\79DP3PO--2\]4+S0H&7X:; MOHP4\K_C@NQ8?G1\^OGXR^FG%4N/E(CRL4LP?[HA%8R0 MA?5&;6&]P6!M/THR^`@G`_G[Q^/=IC6;`;I@"">?$C(?RJ?#:Y(LYQ#S"YS> M8([X^QV>$#K/K29$R-GQ]P4\/V)HOLA@\=F,PHGX;`Y389'3T]//:WO\8N,)E>`S6XS\L9^8+!,D7@:(GA0 M-[M2*0]X,Y*EHHI;IX?=ZF;M;U=*CA:0YCC9L>.T_72IU"7(9$WX-(.0?_0Q M%KD3\QGD(H1DG2GFU=?NE=NQ/E45A$[),LM=>"_^KW0-5QP*MAN!I")=Z9B+ M4`B1D:32<28G.X16E5;]YG.&"6`O^<1!3+FF`"R&TAA#F'%6?)*;Y_CD5,UN M?E$?_WF/P`O*$!=Y1H30YM@L^LS`"\S.CWS)Q?Q`VL9-/NQ+<:>J3N6B4N<1 MO3H*I^:2Q=T*HE`$T*]N+/RD!J M3H05Q9`MY^OIYK$8,O.B_822N=5;)$#9DNAG@R;O`2<#'YZ$BC9J7>0-HNF, MJW]ZP\E%*N*-T`ID8X#2.WP%%HB#3,QUY@3GBM9PXM]`F"J'.?1O#.V\0C\56, MXN(L3:3C&%]H+&EBKGK,!4Z/DH]$.4Y+HCP0G"RI+--KBK@)E5XVPBA07`:L MMU8FX$J,VIC$AU5184`A7/H(7R%>0J/#G73*,A:ZZ-SMJY/-VQ8>\>7BDNQ7 M6B^;"9IAZDKOU_ZPJU?)3J1'K4&UGB!;%[F)7+U2)M@J:@UZK^*-4V)21)

UU$9&L5ME]+N%Z,/I6J*(/>Y6RL_=6CYQ MSR_*E@@&O53?`O-(57=.K M(KFCGHOR`/G-*LF6\A#3[X2D;RC+:HJT::+4]&O2'XQKOB%!2E90O&XEL>K' M*;[JI:BSGL%J([ASJF4GKE6N)N*8<-!*,0,"7#SB"V!C2A:0\O=Q!M9GWD3D M74Y:A3M4]JR2P>.;5Y3%FGUQ; M*"UQ*H+Z6^\.0ZSRJ#PK_$SQ:B?3[.;1!?F)B#YP`5!ZLY(G$/,J,%^?5")H MBZLV33;1R*=)A&X.T-7N;S^&\66IS;GB9E;2/=K4HN5'$?K7(KO=C]6&$>88 M-:679U/1JYS5&X.T#VEM@41/&J%_6^AF][>=D?+_W^+QOSS8*8*+_"7+H5>0 MR7.#%_P*4/HN9D/:O?8V;8H->+\V$4(C1%L[1CPY*K#\/:*EI695;JM##65X MK8EC3'P;UK6\%__W?T#2]5B\ MJ)LCJNRZA!A.&@<5'52;DL9`U?MTS$]+3^K:M,Q3ZWW&+)<"I*VNE;!F:%*> MLAFYQK>^J(*R'T+\B(O\[R".&A^M-/6%AXNIY]QNGZ;2QW#B&Q(KEJGP6L^4 M6@R3X[YGN87DM\(P(C5SA)>BU&3]9CH')ZAWCK5XU:)L;%6H^>H6>FWW_:VV\@ M(?[C1I-%]R*K]*-%QOA*ME%54LW,RT)1'*[64?1XTX-QN>!=K'W7RT[#X\U- MC_KC'B=<"PH35%P'OY@3RM7M\,9DRTFYF6A9*/N+)D:GD#;*509]G>5Z2F5A MM8==L*>%[#V[F@$ZK5<$VF?%SA:GLVT*.'U::^RYM[5/U6V5#W%6$A4#:%@5-JBRB'"UX@EDD!47BQK;\H:G M13"K/XW6FW8]?)S9X!#A$EQ/TS;W'*+/"9M6N@B=YU@_[6-5SV=-=D]R.1S6 M_T9PT$NC]BJ5YC5=<1TL&4.*I-L3"@&#UW#]V^M\B;VI]9B)J6E_J\R02Q'' ME+PBX?_+]Q],[A.JUX/BZ44BJF+=Q?_V#3^VV+T;]F:6FU4"&1-A1.W]R'"1 MOX:S\?I+MZ4ZX:6,MR6O7A-.6[B0;DU7SR^>XLCDLZ48\2W5"KT3"-,\"^;Y M8[3(<^C-"M($L8\\\'&-PX_^XRZ'B_[0H-C6!%O`S:.K"$O*H%Q)MD@DU66! M%KWG.RLM>HUO_!JD7Q>Q`5G;TM">M;4-^PMKX#TO/Y_)12)`0*'QGE4]OK5N M6`2Z%@VCBW@VKY,MC.(3^C1]YZ&O19\1KF\UQ*]?[W7ASD1O@EN3_N!1YC!! ME^!J=J7+JSI,'7!B=`L$3_"%\CMB`L?PWP:*(MDKQHE2D=M(<&IC:J;X$B1S>ZHQ!];R1K M5]_J^\E6HF);V4!T:%#Q4G8+C)CXQW>1V'^UUEW6=<*K]=J]1_$7/R"[--T6 MN-U2#-W5YYYCW__I[G['6Z^,Z*&IC9-/FYK M>30Y-%P%&&(+%61=GBK53:">1V3(R(\V-R^%`,,%:G&/7K7X'W:]3@K;VV6B[4 M--Y;[IUQ?9@X<["=R>&#-\!8.\G3]OZ+)>"3F(O#VE5W,9XI$#HE^?G-7>)#O=MU=UW<`D3SUT&.)NJ0),CN,.-T67E1 M3O<=7Y,D[T(>_A+C3=[GF1`Z+^%$!5?YXT4@27SR/U!+`P04````"`"Z94%` M[5U&LX8&``!D/@``%0`<`'-M960M,C`Q,3$R,S%?9&5F+GAM;%54"0`#4'HI M3U!Z*4]U>`L``00E#@``!#D!``#=6VUSXC80_MZ9_@>&^TP<'GI M,),[,B37Z;<;82^@QI:H)">DO[XK87SXW0@3W'Y)C+7:?7;WD;2VK`\?5X'? M>08A*6>#;O_DM-L!YG*/LOF@&\H>D2ZEW8^__?C#!Y^RITO]9THD=+`?DY7DY>3D_X6+NG)V>]IT_/]\]N`L(2(\RJ0ASH=M!^4MI;MYQ MERAC=*O[:BK\C8)S)[95**%_]39B/7VKUS_KG?=/5M+K1A!U&8UE@4%=$2U5MN&WG5CX6W!=^;7Y[J8I`[G768!?=A`K.._O]U,HK[ MR0412TF9>^+RP-&MSC5WPP"8&C+OABFJ7D=LQD5@@HN6C3KUNH1!5])@Z%'>?/N%P]:YXL`3TSI;F19HL@7WA"N0]>253'W#DW'$V?P017,-4 MV:`K56=-;+R$1[("*THENEM"F("+P\-_'4D9@C=T71[B%,/F#SA/>D1X5L!J M*+5E&YTS.J,NP=DP5GO/?>I2NQA6*+2$B2RF-):2QF!-& M_S%*D+^?B/LT%^BO9P.L1)DEO"O./!SR>NPSB>'WB`(/^:+`K!WCV161BUN? MO\BOC(0>Q58;X%9F#N62F?`6W/>PV%LO#X?UK=3>H9P<+T$8GAPX<;EVFG3J M$_%UZ?BP`%#?;=SCVLG4`A1.(7YCCM6R=7CG#NQ/T@4BW(T7T>6V(W%Y3IER M/!HXD8Q#_!IA+W@@V-3Y^CGEO4%OM#6`"J\Q",C&G@JF\!K5/4""*8@F@2;U-L`T@6"$FXXA5X&M!.*]-;@BFK`0RD#2B?NPDDOGX[ MQ$4N2PU#9T1.#4U#V9L3LG3TLN"`K^3FCEDH>J?]Z'70N^CVMQ@?N@\CO(PK M>9],P1]TBP4453H@>0+.L=S!QS(!^!A[#>O_(Y8-^H3[_BT7+_@PE/+5LG<4 MB)U[)Z/TG8E#D8P73F8;4]&\9CE%SP0/2C/*]XW!=R*1S[T/.,D\>\)]4;LBBRI(KX9 M)]/T9LX$<$*6^+#Q`.*9NK!V>`(NGZ]#97Q/$?*MS$5Y.[RY5M+]C:-KS,3D$I0USS#H]A0/XW\+KC,/B#OHZ1.=5"BI)5T;B0B>U8) M)68BZOW:1NJ9T;$G\^KIJ%$Q_$]XMU,\]JLR[[#2: MVQ8%+-762LJ4X:].>*KW)EW](Z^.$=1'_E M,E%H"F3:L!?P.3%8LQL`R?;L6__/B9WN-Y]7RJ//JUW99FVNLM1;_HV2;>X> ML1C*7=YR#`!!2B!6_S279N\LN%HI`4";4U MW;6!ZJ01NUCX$UF<<:!^,:-%=^-+!)0Q5'(ANE M1NXIT`8M['3XM4&[U8>#H[E=_]%;I7CG7U!+`P04````"`"Z94%`DO#SWK$O M``"Y;0(`%0`<`'-M960M,C`Q,3$R,S%?;&%B+GAM;%54"0`#4'HI3U!Z*4]U M>`L``00E#@``!#D!``#M?6MOVTB:[O<#G/]0R`XP"6`GL;,[B^Z=YH*6Z+30 MCN25Y'3G-`X:M%2VN4.SO"3EV//KMXH7B9>ZLHHL.FF@T5;$]U)B/<];;]W_ M_I]/]R%XA'$2H.BG5R=OW[\",-J@;1#=_O1JEQS[R28(7OVG\W__S]_#(/K' MC^1_UWX"`=:+DA^?DN"G5W=I^O#CNW=?OWY]^_7#6Q3?OCM]__[DW6^?+E:; M.WCO'P=1DOK1!KX"6/[')/OR`FW\-'-:47^ZCL/2P(=W>U],"?*OXU+LF'QU M?')Z_.'D[5.R?544D3R6<%**/[7DB]]T\L,//[S+GNY%L:&`8WK_L_';`R!_ M?S$*X1+>`/+W:CEC:O_PCDB\BV!ZX5_#$+O,U-/G!_C3JR2X?PAA^=U=#&_H M=L(XWILA;^<'\G9._D;>SK\<++_3*=ZMG\+M&J5^:*:46>FWS+F*5P@+=<<:-?Z$L8!VCK1=O^"]YT9:KPJ]2/!X!*VYG^#^B_U)2B MAN2K"_RIYA<^I3#:PFWIF=CFQ,[,=19L,\M[VVA3LQJ25@3%U)^3&;SQD^O, M*F[+;GW_`5L_.7D'PS0IOSDFWQR_/RF:C7\IOO[#W6S0+DJ3)=S`X-&_#B$F M\V07QS!*2W_93_WIE8QH&J3D!_-%W]5_++%>^[DQ3-`NWL"&?YDB_Q%>ATKO MO@:=O/`*?NY#7#B20\#H^&KU"@1;!76GE`#Q7N0(X!8+H!O@AR'Z2II5<(-B ML$6[Z_1F%P*_5,$B?SG]5^!'6_SW;T?81/(`-VGP",/GO[\[O+;VJW;C.KC\ M>%.^`/Q1\-(*B7<;A(OVD![7WM]-C.XE88+4J[.HGHU!G=N="\/C>T:@SFZ_=^>!7%.P2 M6P-NR!0`ZD%`W58U-'0MB14&G)AJU;J[-P_^DU=.KGB<:8*#*LAUCT!%&[A_ M4J&*!/M<.+'8>KK;;4#*X8>7?H`+/?$?`MQQGJ#[>Q2M4K3Y1S-]E58HDU@) M!=U45NC":$(KZXV;ULH9<0YRX`$+'@<1V.2BEM-3>1B@KA752%6%NK6$5=*3 M/>*5/9-S%$^+?DD[RV9T(;OHEG14T]5EIHJW'E+4+OZYM%6V1^^>"OJEEKG= M"5[(0*TW&*]BID9^=?]#X]Q8(MK)LU&(X_33K<&YU-J/+H!E!?J%YO<&<4:^ M.1S&;6:9JQ0'ZGM-_W'F7KCSB0=6/WO>>@5>7T7^ M#J=8FS6Z>GX87R-FC.D=>;Q_/"HQM9SLH_@->[$;5$8^G$" M'F`,$B+UQBYW^-6)%-Y^G1U4\2H=./;ZPHFQW(OKH1-$<"Y5/@/X('H'L M^4L'"",#ZHX0FQG-Q$_NW&A+_GC_L\/)5H@C>N*F$S^.GW%I/_OAK@E,)9WB M)4GJ:%)%RDL/(5;%+X]/\G8<(I/-]V[(!WB0MDLO-6P@C:JKLT]*O>',REWD-;X.(A$&R M9"'_#=\Z8!GM17^(;;!?!V&0!C!ID$7/2/&:NQK1)'@WMR:'+K5* MP`L`&H:=4A<$T6$9Z$.NE@4*/U<$X4'3;F#0!"$R"8EZY.AFKQI*=$HTPM!R MF'B1#B1M%6'8J*KT%B0.3GJ8EE=PVRT.-,PXI42-]8<)^;$2G`(.*3K3*T^6 MO`=M.:HVO0V$26/#N"H.3<#QI-(*O2Z%WQ!H4B;,OVUH,OKX?6'3YHAQNXRS MZ!$GSBB6R3LILLQVHB9KG(P5ZX.T#&U_:AQLZM MTP.,$M(]6:1W,,[7^`NCN(H19GB7,V*O38K*D4H1]FL!O"P@(H M5#.V9,K%%K4_62+=G@Y'DW&UP(L'&/MI$-T6>WD8"X?5%9DM+5O1>/A@N>IW M/%[@52U(<(TYDSML"6>`.!:@4K!H(;-@4!EN_W%LP4`((&X`D*E:$>=9-O@\ MYWNVMW;NL`DO6]"7N+OT#J?]_SP<^%*NF!-+ENOD>)*Z4^5LVR;I*7;#G107 M:#NY`$B(Q%&^YA@S;R^4K4K.O[6\%%FFTI%R[33FO-E*M9END>WQ<&B6)#LQ M?^I2+.Z44J9YD]OME3,U%TI\J6C2N1)D`B/F2:-R>1QIUX2`'[D"EQM5F^/A MQ6*7DH,5R1F5(G)01%D,J8F:IDG%>!]KKL7NE'C35*>3!QVD1LP@&@)X-&+4 ME(!+%2TNH5K6>P9:+^NH)7SJP.V$;*H*R3[8Y-O%%6LEM"%@&5CW+/#0PW)G M"8\ZN#K]'G#%6K9L"%<&%BD+/)A;FRSA2`=.'_;-XBIO%G.I(U"1^[:PQ5IL M;`A;-I<65\I&W>;'>-S.)0UMWFL8[*E_);T7CZ;22`K_\O[M^Q/PX,?@,5M< MOM\%_1_@]/W1^_?OV^,3_P%._NWH_0]_RP8+R<=_^]#HF&43<`>4C.DP5R8D MZ(02[=EK2#)XP]Z)-R15DG1QLX2/,*+PA/)L3Y+:,VV&5*R9I4?;,)\;37F' M?$4V2L7YE[:WH5+K!$F\RB9$*V)U?+;T[8$SGZ>?11MT#]?^4S$/=@8C>!,T MIY7DA$OX"H1U\O1A8)#];84]F/ M03^ED"U0O`^:@"8SVB95V9"VKR>I4X+I@D<#AI*S7JS="S"Y6BZ]^1I^(Q@Z?I MS!=K;P4NW2]N=L'%?`HN%O./QVMO^0E,O;.U78Z(*A`"DAV8C9 M5$E#O*+8-ME;%+N181-+^T"D($,%X9/M.129ZJ5P1U`/=-I0E&B48=JVSI9B M)HA/%+I0@R--(4/TJ)OM@QE4#S*DH"@>^%#,)XZ#"HP*I+"`_;KI!*C+T[!/ MLS@6V,_QJY-!?EN.#OZJG%G\'RSW2(&6$P46-'2=ZOC(N;=<>E.P]#Y[\RMO M5)2@U"R;%?1*X!+CH,+A1M.N17H\Q'`39#A0(IQ2=!> MRO#U+X7='N(RWY/*/3!53:?XQXNX+JA9M9S[8"CUP+\0IGP/G"MA:C;[PTUO M%PC%B<:$1W$[0/1G-I.6Z?*'R\D.&D.YU MAU2S)ON`7`_<*PW9BDZV`/[XFCP$F\K3<8RP"RH4J;S^QF6$5/G:]8,;7&?SZ1B[?`XAPL+KVENYYA M@5%>TRRJ>Z144:V3TV@*C6/2V#8MTV;M/XF7TLJ(U@C$$C7"(KKQ'D99)-R) M:<51=V;SR>*3!];N;[;7G$O5<(LFXIJ@<86NU28,SWK/0#)Y9*[0D0Z&\N-O MR3(4+#/.A;>FH<4^M=8(MNQF,BD&0D`NH2K7SGA/FW!'#A?XB-#V:Q"&K=`L MK[(/T3(JV@P3.S&;_4C[X_--T@R.W6MW_G&6;8Y8K3QR`6D$LWWU_F:SN]^% MI&]=F]`DS_YR^J^G67?V+Z>G_SZF\R*4<(2ZUW.3M&+M.GEEO5GD<'&_"RY; MBZOM1WM.5A]I<^]@S"S'6G;Y7&J(.[.QW'U#J0"*IQRZ?*IGBU3:#5;?!CW/-)0Z34W9B,"R]%MUAJ5FH?>]L5-[6W M=[._I,H4;UOGU.9(-JJ[T3:;_[I#X1;&";FC.7UFAQRN>#L.,<3-X9CJH,^( MQ7,H"7JVB79LR[;OKM:+R2\_+RZFWG+U5^#]U]5L_64T/.$C@DX>8:TQ"475 M9+",XV4``/817;G.=-%7C\-95R=_^&U"31R\C6!MS&%>?#J)E)IDV._CY!*N MHY[.,9'QJ1\&J-OF3_G9_<7<;H,=C"[=GS M54(VM)X'D1]M@NC6)<-/M"ZBNF+Q3E44-4DL[\IX-J?LFL=F16/.W%N#B;OZ M&5PN%Y]G4V\*SKZ`\]G$RT01&_`7A$<-+\?-#/RRB'@;#/7E"\I M(^OL;D"Y\3*6B:J[-)F3=O9N)A@T%AN1-NW\8O'K"IPO%Y]>=)/&RUCUJKQK M3*!EL5U+,K80069=DK1#/LM1Y(<$JF(_H8#B:JA\ENVZ`_]9Q@[Y[!59:#B; MX_\^>ZOU"R`^#SYBP@LJ5HKH%!L2!&=Z'A3!?>>R'+?FX"O.9?>*8\]E>T&S M6BYK%,XCS&4I)57+924,*#=>R')<#Y+)B[V:"`3^7?JJN2Q'D1\2J(K]A`**JZ%R6;;K#OQG&:./S;XN$MLWY5:9 M\8^\YL.6[-@5FX5QY[9]H)FMI>N*O@S'C+UL$Y]T9>57-EN[CTW!5N&:=>_ND-F1G, MDD^RAC7[0):N?G8OR#DDEB_S[8(KI%_?C8M^%:S4KOU5]CXPO(T-IW1Q;!+; M.!G(AE/(QHCL0T7K".1ZH%3$T"]4+2>&0Z.;D7<,!6^[@RM?W0,]IBS.*^EV;`HG9>J%T&LP,TIHK# MST#->'&6W@2WF1=?P&RUNO*FP)U,%E?S;`QGM<:MJ[N$-1, MI+6-U]-O0V6U%]=PFX`7ZY^]93'"9)G#PFI%BC70X!M+I<8BOMT^<6-N/E#DI3-HR#A5Y7EQHA9X M78C8'ILT!B#6H)8V@JRFC:R"L9)"67E1N#67T(D\&$W7))UU(E,]U7H!,9B; M):E4BR2CJ!F.G!]K!%O4"T>9U^)(%.^%*J%)&XI-XWD*VP>/'RPMYS!?/**Y M+U[M(>G772<`1;@*>::M?B!A+`7AV.^`!YQV+%HY1W8\^TL&!"/)Z(8(FXD% M[FQN(-PFY_BE9(<<+![(89:)]P3C39"TKN"2EB]>C(2\)AV$'DPF%K+.>$21 ML^&48H#@%<#B(3EE-"%*`.5:=EDD#P?4L<;J!!.J5NDFZ<B?P(*,97=RZ7)$U9?SD"EQ?N?)U-.9+9 MQDMRZ4%VUJ]U8HDK'*E73(M.3*T&DP36[9'(?\[&2=?(W>!2Q;!YB'"32;+R M)9W$\KJ<$GF0)I;\S4^R/KDDD[+AN-MMD(5=`JA@+P+\$5S%(P\&U+&^&GP3 MJ=9()^=G"/09ZUM(>],&'NYWE'+DI1:2E2/)1W$75'\`9/10S"/0:N^E64!F M0R5J!82*K.:`HVB:F4Q70S00(N=*A.4;+)>K)W%[H?PF0)'V&T@^TA-<;3\O;SYE/=:\_K]DQRA&Z: M>]$Y1<-9>I^]^97MK9VL6D%2K[)Q=WE=L'9I.>N3HS^]6)I^9QTJ>JEW66E>%$G6XMZUU5_%W7R'1B\ MJ%/L2`=`)Y7;S\9Z3Z=99#'OZ30#+9MY^@J&V.;M1QC!V`]Q#\+=W@=10-8I MD;L0-.87L$;C-I;/NM5^3MYS[3$UN(T"W-4@'?W#W@@4XLX'3%@IE)I2R51))5VF2KGI M(<%24VPT!54:^UR=6K>:`J9]F&_`6-V1?\7F( MOK(VX,J(EJT(5U27F1SC1G,[L1\N!T7JSF0QGWISCV=0J!0JD7GD-]G&T:IP36A\#T:0O'U32 M:5.OQVL'I;ST1$:M"P?E[^3J,`358B6?BN.[Z%.50UV((\>6%T.1.4I9VWCEA)E4J0L;ITO5?+^4H7A2 MHTW+@%,T2>NE.U^1\HMCEFZ#UM8)*L_::3O5#BZ]F-V"I>OJ8MS;"@Y=UD6FFB(+S@H6_?R4V`U'\"U[F1 M8OMWMN7[^)H8`OY7/\;_SU6?[484,S!%/:"E'GBTS%:#D8'R68M/^9ZMR2Z. MVQNBJ,^*=]AXIAD/:M:,GV5#L\XC;5N^.%MOF1>>K7R;)\^3:\<)/%. MZRRHB5513=$W7>-:C_"H/;NQ1NW4<8 M^[=POKN_AO'B9AJ$._QMEC*B3L,P4:.\7Q= M/M]9NOVPG>YM`*YS'7=@.L>>DWT?2; M735(^#8;%]4TQ0B:F18L=[2H/2MJ5\I0WZFG,1WI+E)U%&<\/2)V%TC4YVEW M<@R.T/0P-",_)E,;C!E_)7%'7>BU9'.<(ZI[MSC1MD@Y"+]QSWOG*Q848 M%XOY1[#VEI_`QL?9KE18WU24"2YB=EC5!29H<%A'L#[1C M+%HU9*VDIJXU7>[J^>]AV:N9$G&#@`$/^=Z/XS,WWXCUZ=*;KURR4-9R;#`$ M3M0+0AK11<]P+?R8**-])AD;"3!4EIY)=$+F[/;K=-$-J-H!A2&063H"F:UB M"=[^<-?QK.T=)_$80R;C8MXHSAE8^]=AZTPIZL/FAN;BH=8T`MV3WAQ"RR9[ M`J$AZNS_C0E&OK&^;IY:#XC_]AC[?3.9PX2!H!J'GBW@KL?B+L0RO`*KOZ57 MRFNNZHNMQC.E(%Y=);NLBKV>:B0+J?8LN0@B.,,?F]-:;(%FN*P(=`^9E`+] MD?.Y0)%V`!5[8(13D6(UN!()D(F,)<*VJP^IO'!&S-WK%'%7:,T:T,_](/[L MA[O*_B;F0("4;/%&!+*:(9MKO8=)"&.Y[$AF0 M"54Z1&/J4YJ'&*,_:`YC=B?<-S'$OU9>R5_9B?SN[CFS_&K6W1*)?"Z5'L#@@A0MX3_3K1!H6[](/!N.$-& M*K^YK$#)4'VU08?84MX:3K4UV-9PBG?ID")_Z9V)\IC9 M(AM=,.<0%HNNX0IYCMMD.<63[;M#*61ALI2:^,.ME3"AL!A96< M4=4)GZJE(["W!0[&_F09`T-CI=FX>@KE^I7B3BIAWX`AS^P-M.2-Y_\-#_UF M_'1G:CD^S8932^:+!!]G]=M"%L2Y\-A2>!8GZLR]=;F&\?7%8K5Z`RZ] M)5FL]&DQ!ZN?W:5GN=44U3%2JX]&4\?0J+5B7*L]0LA.US0(@U#47(&;U`, M$\Y>4+P-(C]^SM<#K7%8TKQ%=-=):BTL/5"\:[7DP7:O0FW5]$(P7_;HAL/^%<;&,FNZ6:5DF`3-5!@?3%%V(8M),/,S@X5<>!%W'7S;#]J*/@ M]%M`P:DY%)SVA((/IA(NMGGURO_`N%+'3=,XN-ZEY=8YG!M8/P5#!Q\?S.'C M@_6A?MS+\I[(:@M8+,5@S*A*2M>&U#G21D:@F/8-+U^0<"4>Y^%;<`X#P<#[ MC1P'X8'79][<.Y^M+7<\9&N^-!C;.22(Y4+">Z:,C;`Z#X&3%:/$<(R:7^"80 MPQWS[0J949RRD>=-9'4HBL@@K_L4,'>2\V2;F\KILF:.Y."5P]`)'0P7$@=V M4#4/6\R/R@S^(`%^)S)CV6_.K>3V`1\2F-CG\AP5RO$?4@@:\#20[38@\RE^ M>.D'VUDT\1\"W$A3S[R7DBW/"N'+:C%&JAQZC!&Y8#.&K^D<'@/R_#B(0"$Q MDM/SY2H9*=5%XR@2GLJ!,6H(&HXQ2YCZ002WY;H\*E7X0L7[8`EID8/O68\5 M3-ML.C!4G/+[_1)(LKWV)MC@S&HD1!!4(9)[X77HTV4/F)=$Q("+Z.NMU13= MX_(U<,>5*9?/TV6TD,[UJP=TEFDVSND:3C,K`K_G3VPO:^96&9)ZPXV5S#31 M`[#EZG_@V=U9DNS@=KJ+,=4NL_F/;`)Z"9,T#C;DRC$BY9)-MA]CE+0[$!HV MJG/$ZC9,S!2H>NUA0XI..823#IWL.D2+3$J14T+CO6B^[L-V5T8';LVI"IW: MITQFJ)IKS7=T*X\M'A@;NM(J02\4."FFYD"N#')MD*L?Y<<8'8&#B>+JK\S( M$.2.NM+M+`,_1ZC"M7C MP"TKKPQ=0PK;IE/^D[2H63,*4"XWWC#!QY5DB!!6M7QTH)J2C0R<[<8S+-9FY2*$/]@:^5Q9T:"3[H<$(&\?\1ES-?JBD$7XS*3323P@1N!VN MP90K2(>((F.8VQD=S[W4FO@3!Q(%-$@%$X$]B8@B52)KU.B[B94L0C^L$#2V MN867V$$=E"]JK>\@A!EM.ZS12Y4P(-/^#MI/Y;@QN<4_2Q(VVQ6)1UN53(K']9G:6F/8.=KIAL]O6 MN3[X>]4YJLYDL5JO@#N?EHO;+1\2)*Q,I/;BF]O-Z1KU/>8\JZ,A@X`$`O`; M![WQ/1T,!RI(K^[B&#O.9?`MCVL>GHTD0C2CQM(2`EZ]HRH1SC:%USUY4Q+0]PN*[*-65\7$"6PVR=R>CM35^GF,8&RLU]8C07RGMN(;APS!R')DW75 M,60SQ/X*@]N[%&Y=''C\6SC?D67@BYN\B[?8I4F*6T)<LHV\>,SN9='[U9A]_7GM3X'[VENY'+X_T*W"UPM_-YN0X]Q2G MP3^S[QL<5%$IWJN@NC3?NR/PG)REF>3$D#9W@R;)L^NY/O1G1F M)T_;(2WA;)U=W9P-%$T6<])N>O/)S/YHD;B:D7)]M(_B9"@UC^#DVK:X)_V_ M=\7AO&NTA.1U!B&KQ*XG=%N`&-DR'VZV.^` M[\.%)L'[*)3)R-!C^7@AI3>W3L4R(5]JB&WOU]C+5;/_707P\7-X6#V M1N1A"Q3OGB:@&>7:)GL8\&4ZX04:AI*S6'YTY[/_YZYGN`M/'0PGKYS\`5F%5GE)XQF\U<$$ M8[BV"RAL#M"ZFPW:X3!^Z3^3LVHGNY@<5-M,,KE"99K($-)-]*AFC:9J/`_< M9(NMZ)3/P$/^T'*6PZ]`I/*Z&YD&5;Z6*W`LVH1]O(/;B\"_#L(L#6$BGR]W M`#]+3A__=,N&*6KZ$_[,+DB"%*Q@_!AN8K^4D?8/;*+.2;5[DC5[TZ(XVDM&+.Y.C M&CT4L(?>PT!%EA[TZ*L(^6:M8LWXIF)C1.,7?3*(-9;1,THYXQH]>&:.IC#9Q$&VOV=Q,X=?BVXBV044HPA_W&2[M9(Y2K_`U-VBA[2U M657+QGX-2"<;VHM".GCM(7O3*0=_]4A7N\[2FWCS]<47,%NMKL@JLLED<97- M>X/5VIU/W>74\MRW'NR0010TUYUT,%=?B-*Y/+;X8"PYT2I!+U0X(4NK]KID M$!UK@X,ZJ.L#;``\PQ24%3N><7;[A&$TZ/888W7,?Y]:,#.+P[4H-S=PDY); MI[-DXZR9;,PA>T6*4>NM(1Q#UHUUP(R4I]$\;2!:9^$_@ MNKC&AP27_'B+HOODDRW\Y=J2Y[%TC/FV`G?W)?`Z,OF?PV\ZJS71)$N)&J)(5N MM,4E#9+%S24..OB'9F5E;33N;J"HLBX&-(.ENLL>#%O8Y&G3-W-5N! MQ3FX7'HK;[[.UL+9#4@:P$*FJKH>5=1M50-'UY)8P;JQMK^[>_,PQRUXJ5CM M16?[OS)=,EY1U1[1<(1--C`:61MTL-E4+N);/RJVMDU0E*`PV/I%N:L%7MR< M!Y$?;0(_W%\\R=H*8]1F43V&;&K&'2.EZ*'9-5DN7H@RYX>W/AW\7HI:CD]F M@8QZQ%$]B!DQ7XUK!LL[%@8:2P:,EF@0\ITP4N,_>:>.GI="/)LYQG[H8!HD MFQ`ENQ@R,@<)R>*%:C3,EJE@I%P3 M=1)RE*K4$MJVQI=S/XBSI4&'DK%2;1G1XNWP134IPS-NDC,2?GBD$:H[Y^YL M"3Z[%U<>:1W/9W-W/IFY%V`V7ZV75_D)$&,ADU3E(_5*JM.)IU7ED]BZQ0;H M$;>'*'Z6:("$DOL&B".IW0`Q;9MM@$1N^`T07QLW0)\Q71;++Z,AC$SM(N5J M:+8^3*5ZZR.P;7$]Z'4JY`E?:+^BDRZDO42-9M;LR5T<#_PE9DQ%9[Y8XT3L MTOWBGEUXV8C'Q6+^\7CM+3^!J7>V'@U+!'6+5&JBNZ.,-5$2+K/U'3BK]6+R MR_&92X[?)&=O>O/5N,9=#&$3]8&01B31LEN+.`9*:/O0"++*%87!AG,ZF5"P M?G@$5=#,`1(4TST<(L'V(G&0!$O96W0UPN+F;D),#1$%FB MNMM'30@JAGK7N+'M]M89!S!G]H4@5_]8>+.;LEO#T/ M_=LF,VC/2C+4GW7$?ZL$)N#.,DI#-UW6V7\%R'>6`4NM!21X>0U(5L4("AFZ M`X&N.$?B'+X26F@0R16GM'*%--`)`/`=8`!`)RT>QBJH2R;_VQ@&L#(T2Y7R+`P%^BC8[PK1\FRL=[5R9LE-# ME]'`.=6B*9#SC+,0SM9QRD?E%O-Q0)M?;TCR-3=R>)IXB6B.K8'@[.&\)7UF M7D5$?UI>0-1\J@'>ABU3L*6;90&6)NWD7XYH/2&K4I#P33:N>JD+EIBDZ@^* MQE]A&/X2H:_1"OH)BN`VN[0SIF)3(%M#*E-6&[<,RV91S'?"QS1/MT0XD3G^ M!Q$"I51^67P\!KR+*AHIU@>-"PRU.C.XM@?ER6<4XFZG'S^?!R&,FP<(7N^LPV)R'R&].U3"?US!;>ZZ- MV(HULWAM&^:CM2E?8C7_'F0/QH!46O4@B3=*0VE%M([1EHU!$;J$MP&9JXG2 MN7_?A`Y/I(;3IH@V5.L&S:*5:IL/6(I*B=G#(T">C0&VC`I#"/EI=D:%L[H_AY%V?'7K>MBZ=B64*@#G:N@CWJ. M><,4$'L2\$%D8$^.3!!DDL49P@FH"(^"*S(X0%UJBLHBCFZ#4D(O`T]='B90 MS_$WS2$6@51:G[YL21F8P&S8-#V%233ZQ*H8Y18X*])J<,:A7K/8#]K8#.;@W]5J`+Z;O1P=Y M6GU20<]X]3S85U3HP&_9'!CZ:VR6@?;JHP;`\T<&,$T,F89QQ:8(N7O1`UC) M5^-`9^W](_Y[HV.02#5A=]#L@+3D'FXS-)V<%E@BW_QQ&<,'/]AZ3V2M."17 M72_2.Q@70^)NDL"T&5)55(H?)Z?2$932O\,$6E6=T6"L9L,I)$$I"K`LR(3W MUNR''8%-`,)L[RP^4]^_+2RKS,U?][:./80-N4`PV^0&YXDSWQ01H'M[>X0<:] M,D@VHV9'QI4%R4YV#?(#7U/_"5/H(8:/`=HEX3-`CS#.2HJ!0LZ!]G?I'8JS MV_,`?B/YN23$+@ZCNVB;'4&7Z^2[9TB)R+WE^"NBDA\=2\ZLNXTA#KF[!_R9 M(";3J6^#Y&&7PN0M<,,$'9&BA;LM5M[XE9S(EN_7S]$]F;XNAY M_.YC6-0+J29<4@RYO!ZP011!\(P3_;??<(QA'(/32Y!IGV#32Y0Y58DRG*/9 ME)UJ!YG30[M'F(RRYJ[.A6\8BJ<#0O'49#JYPA$E\,/)G1_?-I%+?5;\P,8S M'6[43!E+^6A6F2!O"SO%5R#_SBYTZ16!1.^OCL6:V!YT%&6C=6DV;:*:EZ]5 MG`BM<4/KW^*6_C9?[H]3FS*'24BS3LA6269BF`9Q=IY9F3Z17;I^]/S7A&1' M]R2EOPO@#<[UX0;G"X\0+&YN@@V,WP+B*BE0M,G?.FFE`Y)#86.O3][@Q`#' M<-+H'\?YAE\0I/`^.0*O3]_@S"$ZWOC)7>UNB^J5HV7!C[*(^_K#&Q#BGQ6" M&YAE0KE!DB21@N0I2%#F.>0G6M&$VG9+WN&\/J;[[`G_"7Y5?X?X0\^)O_!5!+`P04````"`"Z94%`W-M% MC]<6``"]8P$`%0`<`'-M960M,C`Q,3$R,S%?<')E+GAM;%54"0`#4'HI3U!Z M*4]U>`L``00E#@``!#D!``#M7>MSVSB2_WY5]S^X/)\3QYF[W4UJ++X3I_A_*$D,.__L]__LKST='3T]/[IY_?4[8X^OCAP_'1__YV>9L\X"5Z M1[*\0%F"#P\X_>>\_/&2)J@H*]TI_GS/TH;!ST>;NK04XO_>-63OQ$_OCC^^ M^_GX_7,^.ZQ%%)\!E33DSQ)]K=/QIT^?CLJO&U+.B!A8;]3FUCLXJ.S':(IO M\/Q`_/O[S86V]*(2W>.45UD6+UY6^,MA3I:K%#>_/3`\5_-)&=NP M$=;Y)*QS_"=AG9^VG(_ZB+=`!9[=T0*EP\A9\I-EE:KI+_354*8UB7PUI)5Y M+\6O8.6=:OH+?8T9H;.OV6S_@G>K&DKXVP*Q5X"*7%E_!?8OM8.H^0-BJYQD MR?N$+BO>9S19+W%63#+>;@4I7BZR.67+DIZD7VR,M3]N(CU$YAS^J__FO- M;7['4):C1-CN6?\5>XD@\/(6Y+6CR[82'&K-3NEQA MKITOS'6T&J M5=Q3A!N<\.Z1OESD^1K/)DE"U]S%9`ONL;,98C,OP0!,?=%&%AF9DP1Q;[AA M>TU3DA`_&UH8>HK)44SRZ?R:X9P;PKM'*-EXBC1E"Y21?Y=,.'Y/4/)MP;B^ M,Q_!#,P\Q3NEV8QW>='WLYR;?R:&88Z7`I=CQW1^BO*'\Y0^Y;]G:#TC_*N/ MX%[5[$NETN$]T'3&8]-J>-BO;L;Z]J7D=(59B9,]-YRRGB&5.D&IF/;>/F!< M;.NXYF-G5CS@@KL00$P*5`Q4U_Z5V[,^;156.U[NDO_0JAL_%YCSW4@D-!E* MR5*&1HJ4)JV*4[&@0YER9E'.*N8HOR^G%NO\W0*AU9&PQA%.B[SYI;3/NP_' M]0K.3_7/?VS0NQ,N7].HFAD`_NXA\Q6CRB5'C:27&* M&'OA45(YU>OHZ52FUAM8IFV'76\Q86V;()8T5?`_6ZY"7LZL*8Y6I7-]ESR0 M=.-EYHPN;6U'_93>E?_S@;**@X(>`%E3QL?T>J&;920-%U`.*@)Q9.98P^>C.WS2 MD7&S6=WAZG1PHOI4&ZW]*5P<&%0`MGN;0]W./[]F.\L1HOCE#SZG72$R^_HL M%GIPSGWVK%&AU*?3H"Y%:BO!BH0+``^5@<"`<:X!\U_1CBMGM8%2_7*:KV)/G$9"56&.08 M#$*Z&:I-I`%BPT$W&T3,K.*-SE4CQ!7-$O``+!,;QN!=X@#QXJ2?#3$V9F-$ M^D/-Z`J4+8C896T4^_J!#QF=.N![5L&[1M!F&]M>1;B-XN";HG M*5>PG/3+6\*:#0S78K6UX<5",(AY#\=.*"L=SFY.LP)<'V$RKZVKB3JKZEVB MT?P#H&$H4+>V=]`SWEU3[S*,US=PC=B:RRJI+$S( M@@CJG0-*I4U!03ZT*K6EWT+0W_$IUC4X+9W:5P>Q\N8#**B^_G@RU!#OH%]N M%>]808LG.V%M8!-A5(@":^P/*5,5;R)(T$<'^K`@,ICH=1IDZ-I/=/":9T_I M["'KA`L\('*!`X=IQU=D$3A'F\\X`;7""2X5ESF7R2).OE.A5W MK?B\AR2DZU3A!6I;0PH$CB]GG5WP!6$>[YQ`UMTZ2%L'Y^#Q8M7)!1\J9M_A MPB$XF/./ETU5^)^/';L'VBS@>$K`\71`9"ASU'Z0F;ZFHAIQ?XZTC[N>^/$\ MG>)W%@A>V4"1W2]'DOTO^0\!W)UO9R3X<9%^]%../R[2=V_BA*!7FM(GT7O. M*3NCZ_MBOD[E"[F:HS8^91L[N)4-^,92#R-`;S2Y5>&Q)J3,81CL2>,?=YY: M79A[?#[>79)'/.L>E]^9RHUZI2SY9%P^4D7]OY^%IL]Y,_*?!MD#`VVX:*#0*>Q?W8]=CWKH?!.E.&\N3$@YA31?FYEE]^MHO=EF?6I3I=U/->Q*;]AE$_/T*"_/&V_R M$JJ1;2/;!"PZLE$5G,[KQE)H)7W;467GVVBHMEJ>FO5H@UK'K8JL6ESBQ?0M M3E.12@=G?`!)N;:3V9)D1&A:D$=KPTA\,*RGZ,50)- MKMS;%191V2D/6A823E3?&CBTOX7=Z@8]'!JWS<5_`A],^EHN-M>H?F?'L+\( MH-S0(UP%0$&%&# MYR1Z?O$NO]FHH\*J7JFMI9S\6[C'&[8VZ?Q@L`)2 M=Y(J1@TL-Y6=D65EWR.@Q6S\!5L8KF#&C1I'>\*/#3>#+D.%&-5!!W;'2,S` M-M[D%U>XT*[T*K\U:Q'M;R&#PJ0&?";<9K*/W!.OV.I-*J7FMHDF3K:1U4;4 MDP6CX`G*26+1KD6C4:VF&0WNUA:A,+W:N-=Q%<#7<(O^-?:N7F8S:=2U=+-(.2;_&Z!=R+!V\HU>#F5=;11&,/AMY(H/WLT^[$KE*( MWNU8>[QK21I%ZZ'!=F_/L[09QOK2;PG(0!OM#A M,NHI7:YH)I`W>2;=Y3(0;5=!-6T(E^I_P\*G=#<1==_EZ_/-]_&O&AO;@]J5 MTEPF5K'M7)=OV,4;P&F2^RO!`:(U/ZH0#VA M3(@'-R#U'`&CXQEO.IF=TR17LKLV::)J5635-^#"!*.>($@W+@0]PCF', M=@A)W4(QC15+GE4>%B.O>(?VC6)\EH8O^)_:@%8BZ$:Q.P1C'BMA&.7X#%?_ M7F3RI.B&INDY94^(=3=Z/$MOCZ&XE1Z_S\AM2OM:0=.3-C751RG<:HBW?WUG M"(49H6)YB15C;Y*]N6>A3/!P?@Y*!0K#$S$>`7!H M4*CR-9ZM&8?X=25;B?SRXW157@?X^HQ90G+I$(,_@UTH.3((&6I];`&&HF,E MT>=AT"A=9C7N@5)[>3-(3>7CPBC8$CT@:JK#_XI0(`B=S/YO75]XNJ.:1;:R MC]ZCCPDDNC$P";0[ M#&*3WE&.H2+_L_-A0[?LF3V1"^,!B'C>#&Z=+-(W\K&C-MYCM]LQ23LD;>\Y MS>;,?WN4DC,6[XF[%-L,Q#W0/K!?*[I%+@-)X'_N+)!^$_L-.3/B MX)?CU'A1WXL[_A!M^;B]I.-C*_;''9D^U7OLU4S]3&/;"O63) MJ)?NO7!A6+P_]M[(T:$AK",*LED=SR7L,(CW;+W;^6>JM:SE^1?;DSMMG@/M M/8=V9OX4Y0_G*7T*X)&7G:;92&4_(:\EE0_&*TC'C"2%.->,/A+>GBPD*+]`! M.H]V4)&JK>WK7%V\9YU:&QYBMR)+2(I;&+NC_9S?/JM0;:$-5D40+VOPOU-< M]D;P$QNV(HJW-O1%1G,/>X4-];)8VY'L0\#NJQ]ZP>)U.;\BD@GC3+,SDJ_J MUQRG\TF>8RGA+HBV;AT+[9L%LHN-7@?!%HD\)KN?*NAF>"'F1*,O%2E7S;O3 M'B-1,^'1$+U9L(*L\CHHU8D2\>6KYP1S8Z#G.L^A?H='89H.?`?AU5SFZL?K MS7:&(6W\.GVFI\0>9V7#\OS?9XKE_8?B_GF9]Q>%PY(Y>YRJ'7N8D*]R;6Q1 MGQ30I]]W+*B]9J$:B%8+P19M]-C3:SXLZ%KU1#^I ME?6[9GB%R*P9"9L7I++9M'C`3+E>TX^)%I\P)M$#U\-6PR(:)H#'!#ETJ#?C MQS5Z$8.'6&U-$K;FHA)T3U+5!+D?$VLT8&82/=0];+6?B,$L0-2/Y'4T;GKU M#>;#EG3I#4RO1:Y$'SU(S188%H]270//+]_0VWNM@WT6\?3S%$^#QI5J5U1ZG.P$, MS)[-R&`T<_&`N;D?G_QK31CF8G-@%"_7*/9*D'3,Y%ZP-H]+P=`. MC4)`0'O8!G2BU""$<`@NE4>_J"HI>\&MERV(F`.J5K3`]#JPRO1O!:,62^P% MFG*=T2^\PBWC/>YXCS?1@M7;-D.@UJ7RR-]V[7F('QXC#7*(WUA=O.>^--J> MDPSQV-X_@@4P,'L4(X,(CLDIY/<^)F?@Y7Q,3LDK-$\-08_3(3B[!4'.VR"7 MVQ$WI3SQGLOG=DHPGN6EPH"\CV#Z)C*VTT<*85=+#`%30)UO;DG&[H[="SH/ M8-&BU-LV0\#5I?+O.R2&!UV#A,3&ZN+=_A:J3K*9^$>L7CVB5"PC5!GCNAMT M'1_B4[3)%>14-'B$]K"$&S;=*O+?&=?[A]&A.>&]D[$7WA%5*8F=RAC!*)6) M%(5FW8>`GU2#_V9]0(\2[`U]D?UZ;R.DU"Z3-IH%XCC>A M0\6:X>F\/D+`->A.W+0$S01-03":ZQBVB2E`_;8[&:3^\:X8=S>>/.Y63-,8#S_`SG"2.KS>@B(>&.H^F$"_*M8U1_!K4% M?1B\'>?5VWQ[MJHZ48DT31)0JS M$C;IO@R$XR6%,1E?YWG<"C5)8X"%QCL$;6](ZJE[YQBSMJ(RP0NP@JC[O+CQ MG!7I2_4PQE;/6Y&<&['9>/W^"C_MF)W1C/^9U%Z:3W4?4+;`^>8B5DG#-2.K MU'!,83".FVV?`3B.F(UD,[!-YP95KFCQ3UQ,9G152+NXO7AL,I=X\1AQ'VTX M'-%A3-C=8^LM8)7#Q$NPJ/WA)E_+B!'/1H8SDB_OE=HX!MUI^4."._(.L^49 MOB]&Z\2BAZ[2#,F@[0D]EX7@`J M^,FNX%IO,0PW5Z/JN(WG?8;!%AW:HAUOUDO*TNOUE2YJ[_@5L8Q/H\01I5+) MT?QB5Q"-Q[.1-3<0M&3C7=;HB*3S/U8ZC8HA^`QKZU"X?NU^KN-<7G30?+B&N!M02`M4`KY69]S$`YXEJ@))5^ M+=!.JM(\+*XZX[YSLN,J[ZNIQ!C-:1 M-W)M3:Y;7X"0UJUN)AVM+ZO$TG5F$*U!W1"Z,ZC%J)NN[0YMJD'T:`OGJ+OT M&4W*SBM2"67<.B\7V9RRY1`KBCE.WB_HX]$,DPK=_(\NJ/E/?U3U:B>/ZJ_- ME+'[M6>W=)/Y!B^(@$E67*%E]V:&B:0E?9=DO+FNQM04I$QG=MOF54YJE3S& MOI3OUN*G7$,F!KT9?OX;[CY#;Z1IM;E$$VZCF]4!MKK$9.P+\-!F/UTS8;ES M[OE1^D^,V-=L=H8*Z1J6A:RY=Z4E"[']@4I9(:#G,W9>'[?._P^@(8.18X^93Z+AI5M>V4Y]S_DLW.+!0 M->>N=%0AP@*FDA4+6C;-JM&'N!!0I4VR8T!!IT1!BRY\'.C5"7 M$!L=[CA;3?/O?NJT>/4IY$96"`]NUZILTY3!+PM.N,RS$H\IZH[]RF_-]>CV MMQ!;TR2^M3D[A9OV#'Z!KX'A=9.+2;'&:Z3I=-8.38CM#%$'W'T[3)IV[[MR MI]\,K;^(_XAST/R7_P=02P,$%`````@`NF5!0*`/U,FI!@``*BT``!$`'`!S M;65D+3(P,3$Q,C,Q+GAS9%54"0`#4'HI3U!Z*4]U>`L``00E#@``!#D!``#M M6M]SFS@0?K^9^Q\8OUSOP;&=M+TF$[=#,$Z8.N`#TFONI2.#;&N*!95$XMQ? M?RMA'#`._M7K=&[\9"'MKK[=3V(EO)\",DYAV&YV3=D/#-(A#0B?= M1LJ;B`>$-#Z\__67RSF_X,$4SY`F$)M@8:,9Y@D*<+7Q\ M/'D\.XG9!(RT.ZW/MP-/S9S+\AD.-\Z:B8(/XBG!S\;'B(^4Z7Q$J33;G>:S M4D3HUQ*:^8A%.9ZSEAP>(8Z7T"OR"_2=\_/SEAI=BH(A4F.:4"X0#7!1/A1+ MA:+PFU8VF(L2^H#YBBC'PEL/9I0L)8,3PLD,"/!4B&F6^C$ MM+FB%V*R'AH,%''!2M,TN=80I;%``M:EZEIT)@FAXWC1`WTRMA:RK: M%Q)%M\')+(ED*%7?E.$Q],'2:>:+Y$O"\`G@RT58'.$:UV6VMJ'NQ&E6&@;3AVS[0]LR=; MGC.P>KH/#U?Z0+<-4_-N3-/WM%?+&7Z_;*W:79TR!:@.?:_:J[M_H;T0J=-< MV6#;*Y;7\'J]16].VX]A>=^"]V7` MN3-VX*VAO-AJ.V_2K.?[=.M][?GPJ^!0+'';X_TYZ(@Z_3 M.`KA6F!^2XEXVI7Q.@OUS)_MR;SG.\;'&V?0,UWO-\W\\\[R[X]K8/\U8"`^ M[4?QX\Z;?8UB/>.O]V3L[>9OFX1W@0Q3QE&!X<]UJWK;_5ZU?3;9F*C8_7KG-G]XZDE$BY0IS` M3AD6_,SH6#>PB8C3"A%7NF>I'3)T30]VBV+D2$&)`H],*!G#.9`*/0A@Q0M" M)T-XGP5P+\K(J!?91,M9A1;/NK:MOF7HMJ_IA@'[PK?L:VT(KS?#,KTC026" M7!R`?]&3Q7F*PV<"($W0$+%P0=)FL4U$O:X0Y9H&[)K!O69YWAVDG0)9D('L MGN[VCFR5V;(H-+&/YOGF*79L8N!-A0'+-IQ;4_/US\=]L1)I.Q:8#]$3&D48 M,O8@IA,?R\_J(Y%%ODY@$Q-O*TS8CF]ZVE"_UZ\&ILKJ`\>^;OJF>ZOUS"O_ MR$XYK3R>)7!.+B3W%\8VCN^8Q\N7(JQN_SQ"L\4!] M]UG$OMJ_*?KGU>AG5WO?U6'9&^I;SS'\*\GX`?R+V5.>BO/'#<'NM-/`^F.V-9*JG6 MP1@H(@'?&<2S5M8\&`8GP98$*)X@]0?&"QA*:A%C):VF MM-/LG#8[;P_'(7;&(/:9OQQ4D;#=FF-P``P-("`!$`&````````0```*2!`````'-M960M M,C`Q,3$R,S$N>&UL550%``-0>BE/=7@+``$$)0X```0Y`0``4$L!`AX#%``` M``@`NF5!0,U`Q0` M```(`+IE04#M74:SA@8``&0^```5`!@```````$```"D@45#``!S;65D+3(P M,3$Q,C,Q7V1E9BYX;6Q55`4``U!Z*4]U>`L``00E#@``!#D!``!02P$"'@,4 M````"`"Z94%`DO#SWK$O``"Y;0(`%0`8```````!````I($:2@``&UL550%``-0>BE/=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`NF5!0-S;18_7%@``O6,!`!4`&````````0```*2!&GH``'-M960M M,C`Q,3$R,S%?<')E+GAM;%54!0`#4'HI3W5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`+IE04"@#]3)J08``"HM```1`!@```````$```"D@4"1``!S;65D M+3(P,3$Q,C,Q+GAS9%54!0`#4'HI3W5X"P`!!"4.```$.0$``%!+!08````` ..!@`&`!H"```TF``````` ` end XML 18 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Dec. 31, 2011
Dec. 31, 2010
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (297) $ (1,604)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 548 499
Loss on disposal of property, plant and equipment 13 0
Stock-based compensation expense 376 507
Excess tax benefits from stock-based award activity (12) (964)
Deferred tax (benefit) expense (161) 552
Changes in operating assets and liabilities:    
Decrease in accounts receivable 465 19
Increase in inventory (713) (383)
Increase in prepaid and other current assets (60) (441)
Increase in accounts payable and accrued liabilities 156 861
(Decrease) increase in deferred revenue (23) 99
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES 292 (855)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of property, plant and equipment (189) (248)
Additions to intangible assets (65) (84)
NET CASH USED IN INVESTING ACTIVITIES (254) (332)
CASH FLOWS FROM FINANCING ACTIVITIES    
Excess tax benefits from stock-based award activity 12 964
Proceeds from exercise of stock options 13 2
NET CASH PROVIDED BY FINANCING ACTIVITIES 25 966
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 63 (221)
CASH AND CASH EQUIVALENTS, beginning of period 18,280 18,068
CASH AND CASH EQUIVALENTS, end of period $ 18,343 $ 17,847

XML 19 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 20 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
ORGANIZATION AND BACKGROUND
6 Months Ended
Dec. 31, 2011
BASIS OF PRESENTATION [Abstract]  
ORGANIZATION AND BACKGROUND
NOTE 1 - ORGANIZATION AND BACKGROUND

The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com, Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.) and Sharps Safety, Inc. (collectively, “Sharps”, “We” or the  “Company”).  All significant intercompany accounts and transactions have been eliminated upon consolidation.
XML 21 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified
Dec. 31, 2011
Jun. 30, 2011
CURRENT ASSETS    
Accounts receivable, allowance for doubtful accounts $ 24 $ 26
INTANGIBLE ASSETS, accumulated amortization $ 242 $ 227
STOCKHOLDERS' EQUITY    
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 20,000 20,000
Common stock, shares issued (in shares) 15,096,291 15,053,316
Common stock, shares outstanding (in shares) 15,096,291 15,053,316
XML 22 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
FAIR VALUE OF FINANCIAL INSTRUMENTS
6 Months Ended
Dec. 31, 2011
FAIR VALUE OF FINANCIAL INSTRUMENTS [Abstract]  
FAIR VALUE OF FINANCIAL INSTRUMENTS
NOTE 11 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, not to be materially different from their carrying values at year-end due to their short-term nature.
XML 23 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document And Entity Information (USD $)
In Millions, except Share data, unless otherwise specified
6 Months Ended
Dec. 31, 2011
Jan. 30, 2012
Dec. 31, 2010
Entity Registrant Name SHARPS COMPLIANCE CORP    
Entity Central Index Key 0000898770    
Current Fiscal Year End Date --06-30    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Accelerated Filer    
Entity Public Float     $ 52.8
Entity Common Stock, Shares Outstanding   15,096,291  
Document Fiscal Year Focus 2012    
Document Fiscal Period Focus Q2    
Document Type 10-Q    
Amendment Flag false    
Document Period End Date Dec. 31, 2011    
XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2011
Dec. 31, 2010
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) [Abstract]        
REVENUES $ 6,212 $ 4,611 $ 11,955 $ 9,844
COSTS AND EXPENSES        
Cost of revenues 4,065 3,385 7,989 6,806
Selling, general and administrative 1,997 2,339 4,207 4,714
Special charge 0 0 0 570
Depreciation and amortization 116 87 223 176
TOTAL COSTS AND EXPENSES 6,178 5,811 12,419 12,266
OPERATING INCOME (LOSS) 34 (1,200) (464) (2,422)
OTHER INCOME        
Other income 9 15 6 28
TOTAL OTHER INCOME 9 15 6 28
INCOME (LOSS) BEFORE INCOME TAXES 43 (1,185) (458) (2,394)
INCOME TAX EXPENSE (BENEFIT)        
Current 2 (981) 0 (1,342)
Deferred 13 603 (161) 552
TOTAL INCOME TAX EXPENSE (BENEFIT) 15 (378) (161) (790)
NET INCOME (LOSS) $ 28 $ (807) $ (297) $ (1,604)
NET INCOME (LOSS) PER COMMON SHARE        
Basic (in dollars per share) $ 0.00 $ (0.05) $ (0.02) $ (0.11)
Diluted (in dollars per share) $ 0.00 $ (0.05) $ (0.02) $ (0.11)
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME (LOSS) PER COMMON SHARE:        
Basic (in shares) 15,077 14,920 15,071 14,914
Diluted (in shares) 15,404 14,920 15,071 14,914
XML 25 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
NOTES PAYABLE AND LONG-TERM DEBT
6 Months Ended
Dec. 31, 2011
NOTES PAYABLE AND LONG-TERM DEBT [Abstract]  
NOTES PAYABLE AND LONG-TERM DEBT
NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT

The Company's Credit Agreement with Wells Fargo Bank, National Association provides for a two-year, $5.0 million line of credit facility, the proceeds of which may be utilized for: (i) working capital, (ii) capital expenditures, (iii) letters of credit (up to $500,000), (iv) acquisitions (up to $1,000,000) and (v) general corporate purposes. As of December 31, 2011, the Company had no outstanding borrowings, $106 thousand in letters of credit outstanding, and $4.9 million of credit available.

Indebtedness under the Credit Agreement is secured by substantially all of the Company's assets. Borrowings bear interest at either (i) a fluctuating rate per annum equal to LIBOR plus a margin of 250 basis points or (ii) at the Company's option, a fixed rate for a 30, 60, or 90 day period set at the option date's LIBOR plus a margin of 250 basis points. Any outstanding revolving loans, and accrued and unpaid interest, will be due and payable on July 15, 2012, the maturity date of the Credit Agreement. The Company pays a fee of 0.2% per annum on the unused amount of the line of credit. The Company estimates that the interest rate applicable to the borrowings under the Credit Agreement would be approximately 3.1% as of December 31, 2011.

The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a minimum level of tangible net worth of $21 million and not exceed a ratio of liabilities to tangible net worth of 1.0 to 1.0. As of December 31, 2011, the Company is in compliance with all financial covenants. The Credit Agreement also contains customary events of default. Upon the occurrence of an event of default that remains uncured after any applicable cure period, the lenders' commitment to make further loans may terminate and the Company may be required to make immediate repayment of all indebtedness to the lenders. The Credit Agreement expires on July 15, 2012.
XML 26 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
INCOME TAXES
6 Months Ended
Dec. 31, 2011
INCOME TAXES [Abstract]  
INCOME TAXES
NOTE 5 - INCOME TAXES

The Company's effective tax rate for the six months ended December 31, 2011 was 35.2% compared to 33.0% for the six months ended December 31, 2010 and 33.8% for the fiscal year ended June 30, 2011.  The effective tax rate for the six months ended December 31, 2011 is higher due the expected impact of state income taxes as a result of forecasted fiscal year 2012 income.

XML 27 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
EQUITY TRANSACTIONS
6 Months Ended
Dec. 31, 2011
EQUITY TRANSACTIONS [Abstract]  
EQUITY TRANSACTIONS
NOTE 9 - EQUITY TRANSACTIONS

During the three and six months ended December 31, 2011 and 2010, stock options to purchase shares of the Company's common stock were exercised as follows:


              
   
Three-Months Ended
  
Six-Months Ended
 
   
December 31,
  
December 31,
 
   
2011
  
2010
  
2011
  
2010
 
   
(Unaudited)
  
(Unaudited)
 
              
Options exercised
  -   -   14,103   2,000 
Proceeds (in thousands)
 $-  $-  $13  $2 
Average exercise price per share
 $-  $-  $0.95  $0.84 


As of December 31, 2011, there was $991 thousand of stock option and restricted stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 2.4 years.
XML 28 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
STOCK-BASED COMPENSATION
6 Months Ended
Dec. 31, 2011
STOCK-BASED COMPENSATION [Abstract]  
STOCK-BASED COMPENSATION
NOTE 7 – STOCK-BASED COMPENSATION

Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee's requisite service period (generally the vesting period of the equity grant).  Total stock-based compensation for the three months ended December 31, 2011 and 2010 was $257 thousand ($18 thousand included in cost of revenues and $239 thousand included in general and administrative expense in the Company's condensed consolidated statement of operations) and $292 thousand ($25 thousand included in cost of revenues and $267 thousand included in general and administrative expense in the Company's condensed consolidated statement of operations), respectively. Total stock-based compensation for the six months ended December 31, 2011 and 2010 was $376 thousand ($38 thousand included in cost of revenues and $338 thousand included in general and administrative expense in the Company's condensed consolidated statement of operations) and $507 thousand ($45 thousand included in cost of revenues and $462 thousand included in general and administrative expense in the Company's condensed consolidated statement of operations), respectively.

Reductions in taxes payable resulting from tax deductions that exceed the recognized tax benefit associated with compensation expense (excess tax benefits) are classified as financing cash flows and as an increase to additional paid in capital. The Company's excess tax benefits included in its cash flows from financing activities for the six months ended December 31, 2011 and 2010 was $12 thousand and $964 thousand, respectively.

In conjunction with the retirement and separation agreement of Dr. Burton Kunik, effective September 30, 2010, the Company recognized an additional $73 thousand in stock-based compensation expense which is included in the Special Charge on the accompanying statement of operations for the six months ended December 31, 2010.

XML 29 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
EARNINGS PER SHARE
6 Months Ended
Dec. 31, 2011
EARNINGS PER SHARE [Abstract]  
EARNINGS PER SHARE
NOTE 8 - EARNINGS PER SHARE
 
Earnings per share are measured at two levels: basic per share and diluted per share. Basic per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted per share is computed by dividing net income by the weighted average number of common shares after considering the additional dilution related to common stock options and restricted stock. In computing diluted earnings per share, the outstanding common stock options are considered dilutive using the treasury stock method. Vested restricted shares are included in basic common shares outstanding, and unvested restricted shares are included in the diluted common shares outstanding, if the effect is dilutive.
 
The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):


   
Three-Months Ended
  
Six-Months Ended
 
   
December 31,
  
December 31,
 
   
2011
  
2010
  
2011
  
2010
 
   
(Unaudited)
  
(Unaudited)
 
              
Net income (loss), as reported
 $28  $(807) $(297) $(1,604)
                  
Weighted average common shares outstanding
  15,077   14,920   15,071   14,914 
Effect of dilutive stock options
  327   -   -   - 
Weighted average diluted common shares outstanding
  15,404   14,920   15,071   14,914 
                  
Net income (loss) per common share
                
    Basic
 $0.00  $(0.05) $(0.02) $(0.11)
    Diluted
 $0.00  $(0.05) $(0.02) $(0.11)
                  
Employee stock options excluded from computation
                
 of dilutive income per share amounts because their
                
   effect would be anti-dilutive
  513   412   538   412 
XML 30 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
INVENTORY
6 Months Ended
Dec. 31, 2011
INVENTORY [Abstract]  
INVENTORY
NOTE 10 – INVENTORY

The components of inventory are as follows (in thousands):

 
   
December 31,
  
June 30,
 
   
2011
  
2011
 
   
(Unaudited)
    
Raw materials
 $1,271  $790 
Finished goods
  1,212   980 
Total
 $2,483  $1,770 
XML 31 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (USD $)
In Thousands, except Share data
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings (Deficit) [Member]
Total
Balances at Jun. 30, 2010 $ 149 $ 19,705 $ 7,087 $ 26,941
Balances (in shares) at Jun. 30, 2010 14,891,754 0 0 0
Exercise of stock options (in shares) 62,500 0 0 0
Exercise of stock options 1 48 0 49
Stock-based compensation 0 871 0 871
Issuance of restricted stock (in shares) 99,062 0 0 0
Issuance of restricted stock 1 (1) 0 0
Excess tax benefit from stock-based award activity 0 979 0 979
Net Loss 0 0 (2,975) (2,975)
Balances at Jun. 30, 2011 151 21,602 4,112 25,865
Balances (in shares) at Jun. 30, 2011 15,053,316 0 0 15,053,316
Exercise of stock options (in shares) 14,103 0 0 0
Exercise of stock options 0 13 0 13
Stock-based compensation 0 376 0 376
Issuance of restricted stock (in shares) 28,872 0 0 0
Issuance of restricted stock 0 0 0 0
Excess tax benefit from stock-based award activity 0 12 0 12
Net Loss 0 0 (297) (297)
Balances at Dec. 31, 2011 $ 151 $ 22,003 $ 3,815 $ 25,969
Balances (in shares) at Dec. 31, 2011 15,096,291 0 0 15,096,291
XML 32 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
RECENTLY ISSUED ACCOUNTING STANDARDS
6 Months Ended
Dec. 31, 2011
RECENTLY ISSUED ACCOUNTING STANDARDS [Abstract]  
RECENTLY ISSUED ACCOUNTING STANDARDS
NOTE 4 – RECENTLY ISSUED ACCOUNTING STANDARDS

There are no recently issued accounting pronouncements that impact the Company's condensed consolidated financial statements as of December 31, 2011.
XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 25 95 1 false 3 0 false 3 false false R1.htm 000990 - Document - Document And Entity Information Sheet http://sharpsinc.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://sharpsinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) false false R3.htm 001010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://sharpsinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) false false R4.htm 002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://sharpsinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) false false R5.htm 003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://sharpsinc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) false false R6.htm 004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://sharpsinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) false false R7.htm 006010 - Disclosure - ORGANIZATION AND BACKGROUND Sheet http://sharpsinc.com/role/OrganizationAndBackground ORGANIZATION AND BACKGROUND false false R8.htm 006020 - Disclosure - BASIS OF PRESENTATION Sheet http://sharpsinc.com/role/BasisOfPresentation BASIS OF PRESENTATION false false R9.htm 006030 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://sharpsinc.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES false false R10.htm 006040 - Disclosure - RECENTLY ISSUED ACCOUNTING STANDARDS Sheet http://sharpsinc.com/role/RecentlyIssuedAccountingStandards RECENTLY ISSUED ACCOUNTING STANDARDS false false R11.htm 006050 - Disclosure - INCOME TAXES Sheet http://sharpsinc.com/role/IncomeTaxes INCOME TAXES false false R12.htm 006060 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT Notes http://sharpsinc.com/role/NotesPayableAndLongTermDebt NOTES PAYABLE AND LONG-TERM DEBT false false R13.htm 006070 - Disclosure - STOCK-BASED COMPENSATION Sheet http://sharpsinc.com/role/StockBasedCompensation STOCK-BASED COMPENSATION false false R14.htm 006080 - Disclosure - EARNINGS PER SHARE Sheet http://sharpsinc.com/role/EarningsPerShare EARNINGS PER SHARE false false R15.htm 006090 - Disclosure - EQUITY TRANSACTIONS Sheet http://sharpsinc.com/role/EquityTransactions EQUITY TRANSACTIONS false false R16.htm 006100 - Disclosure - INVENTORY Sheet http://sharpsinc.com/role/Inventory INVENTORY false false R17.htm 006110 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://sharpsinc.com/role/FairValueOfFinancialInstruments FAIR VALUE OF FINANCIAL INSTRUMENTS false false All Reports Book All Reports Process Flow-Through: 001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: 001010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: 002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2011' Process Flow-Through: 004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Process Flow-Through: Removing column '12 Months Ended Jun. 30, 2011' smed-20111231.xml smed-20111231.xsd smed-20111231_cal.xml smed-20111231_def.xml smed-20111231_lab.xml smed-20111231_pre.xml true true